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ABSTRACT
Orphanin FQ (OFQ) is the endogenous agonist of the opioid receptor-like receptor
(ORL-1). It and its precursor, prepro-OFQ, exhibit structural features suggestive of the opioid
peptides. A cDNA encoding the OFQ precursor sequence in the rat recently has been cloned,
and the authors recently generated a polyclonal antibody directed against the OFQ peptide. In
the present study, the authors used in situ hybridization and immunohistochemistry to
examine the distribution of OFQ peptide and mRNA in the central nervous system of the adult
rat. OFQ immunoreactivity and prepro-OFQ mRNA expression correlated virtually in all
brain areas studied. In the forebrain, OFQ peptide and mRNA were prominent in the
neocortex endopiriform nucleus, claustrum, lateral septum, ventral forebrain, hypothalamus,
mammillary bodies, central and medial nuclei of the amygdala, hippocampal formation,
paratenial and reticular nuclei of the thalamus, medial habenula, and zona incerta. No OFQ
was observed in the pineal or pituitary glands. In the brainstem, OFQ was prominent in the
ventral tegmental area, substantia nigra, nucleus of the posterior commissure, central gray,
nucleus of Darkschewitsch, peripeduncular nucleus, interpeduncular nucleus, tegmental
nuclei, locus coeruleus, raphe complex, lateral parabrachial nucleus, inferior olivary complex,
vestibular nuclear complex, prepositus hypoglossus, solitary nucleus, nucleus ambiguous,
caudal spinal trigeminal nucleus, and reticular formation. In the spinal cord, OFQ was
observed throughout the dorsal and ventral horns. The wide distribution of this peptide
provides support for its role in a multitude of functions, including not only nociception but also
motor and balance control, special sensory processing, and various autonomic and physiologic
processes. J. Comp. Neurol. 406:503–547, 1999. r 1999 Wiley-Liss, Inc.
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Following the cloning of the mu (µ), delta (d), and kappa
(k) receptors, a novel clone also was isolated (Marchese et
al., 1994). This cDNA encoded a putative membrane receptor
with homology to the µ, d, and k opioid receptors (Bunzow
et al., 1994; Wick et al., 1994). Early studies of this new
clone demonstrated that it is homologous to opioid recep-
tors in rat, mouse, and human but is distinct in its
structure and distribution (Chen et al., 1994; Fukuda et
al., 1994; Lachowicz et al., 1994). This orphan clone has
been isolated and named opioid receptor-like (ORL1) recep-
tor to emphasize its relationship to the known opioid
receptors (Mollereau et al., 1994). Splice variants and
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10 dorsal motor nucleus of the vagal nerve
12 hypoglossal nucleus
12n root of the hypoglossal nerve
A5 A5 noradrenaline cells
A7 A7 noradrenaline cells
AAA anterior amygdaloid area
ac anterior commissure
Acb accumbens nucleus
AcbC accumbens nucleus, core
AcbSh accumbens nucleus, shell
ACo anterior cortical amygdaloid nucleus
AD anterodorsal thalamic nucleus
AHA anterior hypothalamic area
AHiA amygdalohippocampal area
AI agranular insular cortex
AL anterior lobe, pituitary gland
alv alveus
AM anteromedial thalamic nucleus
Amb nucleus ambiguous
AMPO anterior medial preoptic nucleus
AOD anterior olfactory nucleus, dorsal
AOL anterior olfactory nucleus, lateral
AOM anterior olfactory nucleus, medial
AOP anterior olfactory nucleus, posterior
AOV anterior olfactory nucleus, ventral
APir amygdalopiriform transition area
APT anterior pretectal nucleus
APTD anterior pretectal nucleus, dorsal part
APTV anterior pretectal nucleus, ventral part
Aq aqueduct
Arc arcuate nucleus
ATg anterior tegmental nucleus
AV anteroventral thalamic nucleus
AVPO anteroventral preoptic nucleus
B basal nucleus of Meynert
BAOT bed nucleus of the accessory olfactory tract
bas basilar artery
bic brachium of the inferior colliculus
BIC nucleus of the brachium of the inferior colliculus
BL basolateral amygdaloid nucleus
BM basomedial amygdaloid nucleus
BSTIA bed nucleus of the stria terminalis, intraamygdaloid division
BSTl bed nucleus of the stria terminalis, lateral division
BSTld bed nucleus of the stria terminalis, lateral division, dorsal part
BSTlj bed nucleus of the stria terminalis, lateral juxtacapsular part
BSTlp bed nucleus of the stria terminalis, lateral posterior part
BSTlv bed nucleus of the stria terminalis, lateral ventral part
BSTma bed nucleus of the stria terminalis, medial anterior part
BSTmpl bed nucleus of the stria terminalis, medial posterolateral part
BSTmpm bed nucleus of the stria terminalis, medial posteromedial part
BSTmv bed nucleus of the stria terminalis, medial ventral part
C1 C1 adrenaline cells
C2 C2 adrenaline cells
C3 C3 adrenaline cells
CA3sl field CA3 of Ammon’s horn, stratum lucidum
CA1–3so fields CA1–CA3 of Ammon’s horn, stratum oriens
CA1–3sp fields CA1–CA3 of Ammon’s horn, stratum pyramidal
CA1–3sr fields CA1–CA3 of Ammon’s horn, stratum radiatum
cc corpus callosum
CC central canal
Ce central amygdaloid nucleus
CeL central amygdaloid nucleus, lateral




CGD central gray, dorsal
CGPn pontine central gray
CI caudal interstitial nucleus, medial longitudinal fasciculus
cic commissure of the inferior colliculus
CIC central nucleus of the inferior colliculus
Cl claustrum
CL centrolateral thalamic nucleus
CLi (B8) caudal linear nucleus of the raphe
CM central medial thalamic nucleus
CnF cuneiform nucleus
cp cerebral peduncle
CPO caudal periolivary nucleus
CPu caudate putamen (striatum)
csc commissure of the superior colliculus
ctg central tegmental tract
cu cuneate fasciculus
Cu cuneate nucleus
DA dorsal hypothalamic area
DC dorsal cochlear nucleus
DCIC dorsal cortex of the inferior colliculus
dcs dorsal corticospinal tract
DEn dorsal endopiriform nucleus
df dorsal fornix
DG dentate gyrus
DGgr dentate gyrus, granule cell layer
DGhi dentate gyrus, hilum
DGmo dentate gyrus, molecular layer
DGpo dentate gyrus, polymorph layer
DH dorsal horn of the spinal cord
Dk nucleus of Darkschewitsch
dlf dorsal longitudinal fasciculus
DLL dorsal nucleus of the lateral lemniscus
DM dorsomedial hypothalamic nucleus
DMSp5 dorsomedial spinal trigeminal nucleus
DMTg dorsomedial tegmental area
DP dorsal peduncular cortex
DPGi dorsal paragigantocellular nucleus
DpMe deep mesencephalic nucleus
DPO dorsal periolivary nucleus
DR (B6, B7) dorsal raphe
DRG dorsal root ganglion
DTg dorsal tegmental nucleus
ECIC external cortex of the inferior colliculus









Gi gigantocellular reticular nucleus
GI granular insular cortex
GiA gigantocellular reticular nucleus, alpha




HDB nucleus of the horizontal limb of the diagonal band of Broca
hi hilum of the dentate gyrus
I–X laminae (I–X) of the spinal cord
I intercalated nuclei of the amygdala
IAD interanterodorsal thalamic nucleus
ICj islands of Calleja
icp inferior cerebellar peduncle
IG indusium griseum
Il intermediate lobe, pituitary gland
IL infralimbic cortex
ILL intermediate nucleus of the lateral lemniscus
IML intermediolateral cell column
IMLF interstitial nucleus of the medial longitudinal fasciculus
IMM intermediomedial cell column
InCo intercollicular nucleus
IntA interposed cerebellar nucleus, anterior part
IntDL interposed cerebellar nucleus, dorsolateral part
IntDM interposed cerebellar nucleus, dorsomedial part
IntP interposed cerebellar nucleus, posterior part
IO inferior olive
IOA inferior olive, medial subnucleus A
IOB inferior olive, medial subnucleus B
IOD inferior olive, dorsal
IODM inferior olive, dorsomedial
IOM inferior olive, medial
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Abbreviations
IOPr inferior olive, principal
IPC interpeduncular nucleus, caudal
IPD interpeduncular nucleus, dorsal
IPL interpeduncular nucleus, lateral
IPN interpeduncular nucleus
IPR interpeduncular nucleus, rostral
IPRL interpenduncular nucleus, rostrolateral
IRt intermediate reticular nucleus
KF Kolliker-Fuse nucleus
La lateral amygdaloid nucleus
LA lateroanterior hypothalamic nucleus
Lat lateral (dentate) cerebellar nucleus
LatC lateral cervical nucleus
LatPC lateral cerebellar nucleus, parvocellular part
LC locus coeruleus
Ld lambdoid septal zone
LD laterodorsal thalamic nucleus
LDTg laterodorsal tegmental nucleus
lfp longitudinal fasciculus of the pons
lfu lateral funiculus of the spinal cord
LGN lateral geniculate nucleus
LH lateral hypothalamic area
LHb lateral habenula
ll lateral lemniscus
LM lateral mammillary nucleus
lo lateral olfactory tract
LO lateral orbital cortex
LOT nucleus of the lateral olfactory tract
LP lateral posterior thalamic nucleus
LPB lateral parabrachial nucleus
LPGi lateral paragigantocellular nucleus
LPO lateral preoptic area
LRt lateral reticular nucleus
LS lateral septal nucleus
LSD lateral septal nucleus, dorsal
LSI lateral septal nucleus, intermediate
LSO lateral superior olive
LSp lateral spinal nucleus
LSV lateral septal nucleus, ventral
LV lateral ventricle
LVe lateral vestibular nucleus
LVPO lateroventral periolivary nucleus
MA3 medial accessory oculomotor nucleus
MCPC magnocellular nucleus of the posterior commissure
MCPO magnocellular preoptic nucleus
MD mediodorsal thalamic nucleus
MdD medullary reticular nucleus, dorsal
MdV medullary reticular nucleus, ventral
ME medial eminence
Me5 mesencephalic trigeminal nucleus
MeAD medial amygdaloid nucleus, anterodorsal
MeAV medial amygdaloid nucleus, anteroventral
Med medial (fastigial) cerebellar nucleus
MedDL medial cerebellar nucleus, dorsolateral protuberance
MePD medial amygdaloid nucleus, posterodorsal
MePV medial amygdaloid nucleus, posteroventral
MGN medial geniculate nucleus
MHb medial habenula
MiTg microcellular tegmental nucleus
ml medial lemniscus
ML medial mammillary nucleus, lateral part
mlf medial longitudinal fasciculus
MM medial mammillary nucleus, medial part
MMn medial mammillary nucleus, median part
MnR (B5) median raphe nucleus
MO medial orbital cortex
mo molecular layer of the dentate gyrus
Mo5 motor trigeminal nucleus
mp mammillary peduncle
MPA medial preoptic area
MPB medial parabrachial nucleus
MPO medial preoptic nucleus
MS medial septal nucleus
MSO medial superior olive
mt mammillothalamic tract
MTu medial tuberal nucleus
MVe medial vestibular nucleus
MVeV medial vestibular nucleus, ventral
MVPO medioventral periolivary nucleus
Oc occipital cortex
opt optic tract
OPT olivary pretectal nucleus








PC paracentral thalamic nucleus
PCom nucleus of the posterior commissure
PCRt parvocellular reticular nucleus
PDTg posterodorsal tegmental nucleus







PLCo posterolateral cortical amygdaloid nucleus
PLd paralambdoid septal nucleus
PLi posterior limitans thalamic nucleus
PMCo posteromedial cortical amygdaloid nucleus
PMD premammillary nucleus, dorsal
PMR paramedian raphe nucleus
PMV premammillary nucleus, ventral
Pn pontine nuclei
PN paranigral nucleus
PnC pontine reticular nucleus, caudal
PnO pontine reticular nucleus, oral
PnR pontine raphe nucleus
PnV pontine reticular nucleus, ventral
Po posterior thalamic nucleus group
PP peripeduncular nucleus
PPT posterior pretectal nucleus
PPTg pedunculopontine tegmental nucleus
PR prerubral field
Pr5 principal sensory trigeminal nucleus
PrC precommissural nucleus
PrH prepositus hypoglossal nucleus
PrS presubiculum
PT paratenial nucleus
PVA paraventricular thalamic nucleus, anterior
PVNm paraventricular hypothalamic nucleus, magnocellular
PVNp paraventricular hypothalamic nucleus, parvocellular





Re reunions thalamic nucleus
Rh rhomboid thalamic nucleus
RI rostral interstitial nucleus, medial longitudinal fasciculus
RLi rostral linear nucleus of the raphe
RMC red nucleus, magnocellular
RMg (B3) raphe magnus nucleus
ROb (B2) raphe obscurus nucleus
RPa (B1) raphe pallidus nucleus
RPC red nucleus, parvocellular




RSA retrosplenial agranular cortex
RSG retrosplenial granular cortex
Rt reticular thalamic nucleus
RtTg reticulotegmental nucleus of the pons
S subiculum
s5 sensory root of the trigeminal nerve
SC superior colliculus
SC(DpG) superior colliculus, deep gray layer
SC(DpWh) superior colliculus, deep white layer
SC(InG) superior colliculus, intermediate gray layer
SC(InWh) superior colliculus, intermediate white layer
SC(Op) superior colliculus, optic nerve layer
SC(SuG) superior colliculus, superficial gray layer
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possible brain heterogeneity of this receptor have been
reported (Wang et al., 1994; Mathis et al., 1997) as well as
its presence outside of the central nervous system (CNS;
Halford et al., 1995). Functional studies of this receptor
have demonstrated that, similar to opioid receptors, its
activation stimulates GTPgS binding and inhibits adenyl-
ate cyclase (Wu et al., 1997). However, the expressed ORL1
receptor has a poor affinity for the known opioid ligands
(Meng et al., 1996; Sim et al., 1996; Ma et al., 1997).
Binding and mutation analyses have established that
ORL1 has features that specifically exclude known opioids
and promote the high-affinity binding of its own endog-
enous ligand (Standifer et al., 1994; Meng et al., 1996;
Mollereau et al., 1996a).
In the pursuit to identify a neuropeptide that activates
the ORL1 receptor, orphanin FQ (OFQ), a novel heptadeca-
peptide also referred to as nociceptin, recently was discov-
ered. OFQ exhibits structural features suggestive of endog-
enous opioid peptides (Civelli et al., 1997) and has been
shown to be an endogenous agonist of the ORL1 receptor
(Meunier et al., 1995; Reinscheid et al., 1995; Saito et al.,
1995, 1996, 1997). This novel peptide demonstrates spe-
cific binding characteristics with the ORL1 receptor (Dooley
and Houghten, 1996; Reinscheid et al., 1996; Shimohiga-
shi et al., 1996; Ardati et al., 1997; Butour et al., 1997;
Guerrini et al., 1997). In addition, high-affinity binding of
OFQ peptide fragments with the ORL1 receptor recently
has been reported (Dooley et al., 1997). Orphanin FQ has
been shown to depend on peptidase metabolism (Montiel et
al., 1997; Noble and Roques, 1997), to stimulate ORL1-
induced Ca21 and K1 conductance changes (Connor et al.,
1996, 1997; Knoflach et al., 1996; Nicol et al., 1996;
Vaughan and Christie, 1996; Abdulla and Smith, 1997;
Ikeda et al., 1997; Vaughan et al., 1997; Yu et al., 1997;
Wagner et al., 1998) and protein kinase C activation (Lou
et al., 1997), and to effect function of other neurotransmit-
ter systems (Faber et al., 1996; Giuliani and Maggi, 1996;
Murphy et al., 1996; Wang et al., 1996; Gintzler et al, 1997;
Liebel et al., 1997). Unlike other opioid peptides, OFQ fails
to produce cross tolerance with morphine (Hao et al., 1997)
or conditioned place preference (Devine et al., 1996b).
However, it has been implicated subsequently in many
other physiologic and behavioral processes, including car-
diac and vascular control (Champion and Kadowitz,
1997a,b; Champion et al., 1997; Gumusel et al., 1997),
diuresis (Kapusta et al., 1997), feeding (Pomonis et al.,
1996), learning (Sandin et al., 1997), locomotion (Devine et
al., 1996a; Florin et al., 1996, 1997a), and nociception
(Grisel et al., 1996; Mogil et al., 1996a,b; Rossi et al., 1996,
1997; Stanfa et al., 1996; Xu et al., 1996; Dawson-Basoa
and Gintzler, 1997; Heinricher et al., 1997; King et al.,
1997; Liebel et al., 1997; Morgan et al, 1997; Nishi et al.,
1997; Tian et al., 1997a,b; Yamamoto et al., 1997; Zhu et
al., 1997). Its possible role as an anxiolytic also has been
reported (Moreau et al., 1997).
OFQ is derived from a larger precursor, prepro-OFQ,
which shares structural homology to the opioid peptide
precursors, prodynorphin and preproenkephalin, and it
has been suggested recently that a coordinated mecha-
nism of evolution has separated the OFQ system from the
opioid system (Reinscheid et al., 1998). The primary
structure of the rat and human OFQ precursor has re-
cently been reported, as has tissue distribution of preproor-
phanin mRNA in rat (Mollereau et al., 1996b; Nothacker et
al., 1996) and mouse (Houtani et al., 1996; Pan et al.,
1996). Antisera to OFQ have been produced, and detection
Abbreviations
SC(Zo) superior colliculus, zonal layer
SCh suprachiasmatic area
scp superior cerebellar peduncle
Sd subiculum, dorsal






sm stria medullaris of the thalamus
SNC substantia nigra, pars compacta
SNL substantia nigra, pars lateralis




Sol nucleus of the solitary tract
SolC nucleus of the solitary tract, commissural
SolL nucleus of the solitary tract, lateral
SolM nucleus of the solitary tract, medial
SOR supraoptic nucleus, retrochiasmatic (diffuse)
sp stratum pyramidal
sp5 spinal trigeminal tract
Sp5C spinal trigeminal nucleus, caudal
Sp5I spinal trigeminal nucleus, interpolar
Sp5O spinal trigeminal nucleus, oral
SPFPC subparafascicular thalamic nucleus, parvocellular
SPO superior paraolivary nucleus
SPTg subpeduncular tegmental nucleus









SuVe superior vestibular nucleus
T temporal cortex
TC tuber cinereum
Te terete hypothalamic nucleus
TM tuberomammillary nucleus




Tz nucleus of the trapezoid body
VCA ventral cochlear nucleus, anterior
VCP ventral cochlear nucleus, posterior
VDB nucleus of the vertical limb of the diagonal band of Broca
VEn ventral endopiriform nucleus
vfu ventral funiculus of the spinal cord
VH ventral horn of the spinal cord
VL ventrolateral thalamic nucleus
VLL ventral nucleus of the lateral lemniscus
VLTg ventrolateral tegmental nucleus
VM ventromedial thalamic nucleus
VMH ventromedial hypothalamic nucleus
VO ventral orbital cortex
VP ventral pallidum
VPL ventral posterolateral thalamic nucleus
VPM ventral posteromedial thalamic nucleus
VTA ventral tegmental area
VTg ventral tegmental nucleus
ZI zona incerta
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of OFQ-like immunoreactivity has been reported in the
spinal cord (Riedl et al., 1996; Lai et al., 1997; Schuligoi et
al., 1997) and other structures within pain-modulatory
regions in the rat (Schulz et al., 1996), and the hypothala-
mus of the rodent and monkey (Quigley et al., 1998).
Autoradiographic analysis of 3H-OFQ receptor binding
and immunohistochemical analysis of the ORL1 receptor
have been reported in rat, mouse, and human (Anton et al.,
1996; Florin et al., 1997b; Makman et al., 1997), as has
agonist-stimulated binding of 35S-labeled GTPgS to the
ORL1 receptor in the guinea pig brain (Sim and Childers,
1997). No such critical anatomic analysis of OFQ has been
reported to date. In this study, by using antisera that were
generated against the orphanin heptadecapeptide, and
35S-labeled cRNA corresponding to the 58 portion of the
prepro-OFQ precursor sequence, we performed in situ
hybridization and immunohistochemistry to analyze the
distribution of prepro-OFQ mRNA expression and OFQ
peptide immunoreactivity in the adult rat forebrain, brain-
stem, and spinal cord.
MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats (Charles River, Por-
tage, MI; 250–300 g) were used for all in situ and immuno-
cytochemistry studies. Handling and use of all animals
strictly conformed to National Institutes of Health guide-
lines. In addition, protocols for animal use in this study
were approved by the University Unit for Laboratory
Animal Medicine (ULAM) at the University of Michigan
Medical Center.
Tissue preparation
For in situ hybridization, adult male Sprague-Dawley
rats were killed by decapitation, and their brains were
removed and immediately frozen in isopentane at 230°C.
In addition to whole brains, the pituitary gland and a
portion of the cervical and thoracic spinal cord were
dissected from each animal and similarly frozen. Brain,
pituitary, and spinal cord tissue were stored at 280°C
until sectioning. All CNS material was sectioned coronally
on a Bright cryostat at 15 µm, thaw mounted on polylysine-
subbed microscope slides, and then stored at 280°C until
use.
For immunohistochemistry, adult male Sprague-Dawley
rats were deeply anesthetized with 75 mg/kg of sodium
pentobarbital i.p. and transcardially perfused with approxi-
mately 50–75 ml of 0.9% NaCl containing 2.2% sodium
nitrite. This was followed with approximately 400 ml of
Zamboni’s fixative (Zamboni and De Martino, 1967). Seven
animals were injected with colchicine (300 µg in 7.5 µl of
sterile saline, i.c.v.) 48 hours prior to transcardiac perfu-
sion. After perfusion was completed, the brain, pituitary,
and portions of the thoracic and cervical spinal cord were
removed and postfixed in Zamboni’s fixative for 1 hour.
Tissue was then transferred to a solution of 10% sucrose in
50 mM potassium phosphate-buffered saline, pH 7.2
(KPBS), for 24–48 hours. Brains were frozen in liquid
isopentane at 230°C, then stored at 280°C until section-
ing. All material was sectioned coronally on a Leica
CM1800 cryostat at 30 µm and stored in cryoprotectant
(sodium phosphate buffer, pH 7.4, with 0.9% saline, 30%
sucrose, and 30% ethylene glycol) at 220°C until use.
cRNA probe
Hybridization of CNS tissue was performed by using
35S-UTP and 35S-CTP-labeled riboprobes generated against
the rat prepro-OFQ mRNA sequence. A polymerase chain
reaction fragment corresponding to the 58 portion of the
prepro-OFQ sequence was used to prepare a 35S-labeled
cRNA probe. This cDNA fragment spans 580 base pairs
(bases 106–686) and contains the entire open reading
frame of the prepro-OFQ precursor molecule (Houtani et
al., 1996; Mollereau et al., 1996b; Nothacker et al., 1996).
Antibody production
The entire OFQ heptadecapeptide (FGGFTGARK-
SARKLANQ) was used for polyclonal antibody production.
The purity of this peptide and its activity at the ORL-1
receptor have been reported previously (Reinscheid et al.,
1995). By using glutaraldehyde, OFQ was conjugated to
thyroglobulin, and additional free aldehyde sites were
blocked by saturating the solution with glycine. OFQ
thyroglobulin conjugates were then divided into aliquots
and delivered to HRP Inc. (Denver, PA), where rabbit
anti-OFQ antiserum was produced.
At HRP Inc., antisera was generated by inoculating
rabbits (New Zealand White; n 5 2) with 350 µg of the
thyroglobulin-conjugated OFQ peptide suspended in com-
plete Freund’s adjuvant. Rabbits were injected initially
once a week for 3 weeks, given 2 weeks rest, and then bled
on week 6. On week 7, the animals were inoculated with
190 µg of conjugated peptide suspended in incomplete
Freund’s adjuvant. They were allowed to rest on week 8
and were bled on week 9. This second inoculation-rest-
bleed procedure was continued until a total of eight bleeds
were obtained, after which the rabbits were exsangui-
nated. Sera obtained from each rabbit were tested immuno-
histochemically for each bleed. Based on initial results,
antisera from animal 217, bleeds 5 and 6, were affinity
purified by using the OFQ heptadecapeptide coupled to a
sepharose-4B-cyanogen bromide column. After final analy-
sis, affinity-purified antiserum from animal number 217,
bleed 6, was used in this study.
Immunohistochemistry
The immunohistochemistry technique employed in this
study has been described previously for detection of the µ
and k opioid receptors in the rat CNS (Mansour et al.,
1995a, 1996). Floating rat brain and spinal cord sections
were washed in 50 mM KPBS to remove cryoprotectant.
Sections were then incubated for 30 minutes in 0.3% H2O2
and rinsed in 50 mM KPBS. Next, tissue was incubated
with an avidin-D blocking agent for 15 minutes, rinsed
with 50 mM KPBS, and followed with a 15-minute incuba-
tion with a biotin-blocking solution (blocking agents ob-
tained from Vector Laboratories, Burlingame, CA). Prior to
the addition of primary antibody, sections were incubated
for 60 minutes in bovine serum albumin (BSA) diluent (50
mM KPBS with 0.9% NaCl, 1% BSA, 1% normal goat
serum, and 0.4% Triton X-100), then transferred to a
solution containing affinity-purified OFQ antibody diluted
to 1:1,500 with BSA diluent, and incubated at 24°C for
36–48 hours. After primary antibody incubation, the sec-
tions were washed in KPBS and incubated with biotinyl-
ated goat anti-rabbit immunoglobulin G (IgG; 1:1,000) for
60 minutes at room temperature, followed by an avidin-
biotin complex (ABC) coupled to horseradish peroxidase
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(1:1,000; Vector Elite; Vector Laboratories) for 60 minutes,
also at room temperature. Immunostaining was visualized
with a 0.04% solution of 3,38-diaminobenzidine tetrahydro-
chloride (DAB) containing 2.5% nickel chloride and 0.01%
H2O2 dissolved in 0.1 M sodium acetate. After 6 minutes in
DAB, the reaction was terminated by two consecutive
washes in 0.9% NaCl. Sections were mounted from 0.9%
NaCl onto polylysine-subbed microscope slides, dehy-
drated with graded alcohols followed by xylene, and cover-
slipped with Permount. Tissue sections adjacent to those
that were stained immunohistochemically were mounted
onto polylysine-subbed slides and Nissl counterstained
with cresyl violet to aid in anatomic localization. Immuno-
histochemical brightfield staining was viewed with a Zeiss
Axiphot microscope (Thornwood, NY) and a Leitz DM RD
microscope (Wetzlar, Germany) with camera attachment.
Representative sections were photographed, and images
from negatives were generated on high-quality Kodak
photographic paper for illustrations (Rochester, NY) for
illustrations. Processing of all photomicrographs was per-
formed under identical darkroom conditions.
In situ hybridization
The in situ hybridization technique employed in this
study has been described previously for detection of opioid
receptor mRNA in the rat CNS (Mansour et al., 1993,
1994). Adjacent sections of frozen brain, pituitary, and
spinal cord with dorsal root ganglia were removed from
storage (280°C) and placed into 4% paraformaldehyde for
60 minutes at room temperature. Sections were next given
three 5-minute rinses in a solution of 300 mM sodium
chloride and 30 mM sodium citrate, pH 7.2 (SSC; 2 3 SSC),
followed by treatment with proteinase K [1 µg/ml in 100
mM Tris and 50 mM ethylenediamine tetraacetic acid
(EDTA), pH 8.0] for 10 minutes at 37°C. Sections were
rinsed once in water then treated with 0.1 M triethanol-
amine and acetic anhydride (400:1 volume/volume), pH
8.0, for 10 minutes at room temperature. Sections were
rinsed again in water, dehydrated in graded alcohols, and
air dried.
Prepared tissue was hybridized with a 35S-UTP- and
35S-CTP-labeled riboprobe generated to the rat OFQ pep-
tide precursor as described above. The cRNA probe was
diluted by using a hybridization buffer composed of 75%
formamide, 10% dextran sulfate, 3 3 SSC, 0.1 mg/ml yeast
tRNA, 1 3 Denhardt’s, and 10 mM dithiothreitol in 50 mM
Na2 PO4, pH 7.4. The activity of 35S-labeled cRNA used for
hybridization was in the range of 1–2 3 106 cpm/35 µl.
Volumes of 35 µl of diluted probe were applied to tissue
sections, and glass coverslips were placed, keeping the
hybridization buffer in contact with tissue. Slides were
placed in sealed humidifying chambers containing 50%
formamide and hybridized overnight in a VRW Scientific
1535 incubator (Cornelius, OR) at 55°C.
On day 2, glass coverslips were removed, and slides were
rinsed twice in 2 3 SSC for 5 minutes, then treated with
RNase A for 60 minutes at 37°C (200 µg/ml RNase A and
0.5 M NaCl in 100 mM Tris, pH 8.0). Following RNase A
treatment, sections were washed in 2 3 SSC for 5 minutes,
followed by 1 3 SSC for 5 minutes, and 0.5 3 SSC for 5
minutes, all at room temperature. Low salt wash was
completed with incubation in 0.1 3 SSC for 60 minutes at
65°C. Sections were then rinsed in water, dehydrated
through graded alcohols, and air dried.
On completion of hybridization, slide-mounted sections
were opposed to Kodak XAR-5 x-ray film for 5 days then
dipped in NTB2 film emulsion. Brain sections were then
developed following a 30-day exposure to NTB2 emulsion.
The exposure time was chosen to maximize the detection of
in situ hybridization grains and was determined empiri-
cally by periodic development of test slides of tissue
sections dipped in the NTB2 emulsion. Following develop-
ment of the NTB2 film emulsion, all slides were rinsed in
running water at room temperature for 30 minutes and
Nissl counterstained with cresyl violet, dehydrated in
graded alcohols followed by xylene, and coverslipped with
Permount. Hybridized tissue was analyzed by using a
‘‘Dark-Lite’’ darkfield stage light on a Leitz DM RD micro-
scope with camera attachment. Representative sections
were photographed, and images from negatives were gen-
erated on high-quality Kodak photographic paper for
illustrations. Like the immunohistochemical images, all
processing was done under identical darkroom conditions.
Controls
For immunohistochemical controls, the OFQ antibody
was preabsorbed by incubating the primary antiserum
with 25 µM of the OFQ heptadecapeptide overnight prior
to the addition of floating tissue sections. Preabsorption
controls and normal immunohistochemical studies were
performed on adjacent tissues from both normal and
colchicine-treated animals.
The specificity of the 58 portion of the prepro-OFQ
sequence used for in situ hybridization was determined
with two separate control conditions. After the 60-minute
incubation in 4% paraformaldehyde, sections from repre-
sentative brain regions were incubated in RNase A for 60
minutes at 37°C (200 µg/ml RNase A and 0.5 M NaCl in
100 mM Tris, pH 8.0). They were then run through the
entire hybridization procedure with 35S-labeled cRNA, as
described above. A separate set of adjacent, representative
brain regions was run through the entire hybridization
procedure as described above, with the exception that a
35S-labeled mRNA (sense strand) was used for the hybrid-
ization. Other than the alterations described above (RNase
A and sense controls), all control tissue was treated
identically and ran along side adjacent sections under
normal conditions for comparison.
RESULTS
Colchicine treatment
Colchicine injection into the lateral ventricle markedly
altered OFQ immunohistochemical staining in all animals
studied. Brains of untreated animals contained more
robust fiber staining than what was observed in colchicine-
treated animals, but they also demonstrated very few
immunolabeled cell bodies. Areas of heaviest immunolabel-
ing (e.g., lateral septum, bed nucleus of the stria termina-
lis, central nucleus of the amygdala, arcuate nucleus,
central gray, nucleus of Darkschewitsch, solitary nucleus)
did contain some labeled perikarya in untreated animals.
Untreated (normal) animals provided an added source of
information concerning the distribution of OFQ fiber and
terminal immunoreactivity, complimenting fiber and cell
staining observed in colchicine-treated animals. Descrip-
tions presented here are a synthesis of immunolabeling
observed in both colchicine-treated and normal animals,
with descriptions of cell labeling derived primarily from
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colchicine-treated animals, and fiber/terminal labeling
derived primarily from untreated animals (Fig. 1).
Controls
No mRNA expression was detected in tissues pretreated
with RNase A prior to in situ hybridization using 35S-
labeled cRNA directed to the 58 portion of the prepro-OFQ
cDNA sequence (antisense). Messenger RNA levels in
these tissues were negligible in all levels of the forebrain,
brainstem, and spinal cord. In addition, no mRNA-
expressing cells were detected in tissues hybridized with a
35S-labeled mRNA directed to the 58 portion of the prepro-
OFQ cDNA sequence (sense strand). Like the RNase A
treatment, these tissues contained no mRNA-expressing
cells at all levels studied (Fig. 2).
Unanticipated, nonspecific background staining noted
during initial immunohistochemical trials was found to be
due to impurities in the ABC-horseradish peroxidase
reaction kit obtained from Vector Laboratories (Vector
Elite kit). Nonspecific background staining was removed
completely by using an avidin-D and biotin-blocking solu-
tion, also provided by Vector Laboratories. Therefore,
these blocking agents were used in all immunohistochemi-
cal studies reported below.
Preabsorption of the primary OFQ antibody with OFQ
heptadecapeptide virtually eliminated all immunolabeling
(Fig. 3). However, there were two notable exceptions. A
densely stained group of cell bodies was observed clustered
lateral to the paraventricular nucleus of the hypothalamus
in a perifornical distribution dorsal to the anterior hypotha-
lamic area. Within this prominently immunolabeled cell
group, a very small population of these neurons was not
blocked completely in preabsorption controls. Unblocked
perikarya were visible but were labeled very lightly.
Within the forebrain, the neurons within this cell group
were the only perikarya that were not blocked completely
in preabsorption controls. Preabsorption of the OFQ anti-
body with the OFQ peptide completely blocked immunore-
activity in every other forebrain region. In the cerebellum,
dense staining of perikarya was observed throughout the
Purkinje cell layer in preabsorption controls. These immu-
nolabeled cells, which were confined to the cerebellum,
were considered to be nonspecific because 1) they were
present equally in both colchicine-treated and untreated
animals, 2) this cell population was confined to the Pur-
kinje layer and remained completely unblocked in all
preabsorption control studies, and 3) no mRNA expression
was observed in this cell layer at any brainstem level.
Therefore, in the cerebellum, the Purkinje cell layer was
considered to be void of specific immunolabeling. In con-
trast, immunolabeling in the granular layer and deep
cerebellar nuclei is treated as specific, because cerebellar
labeling in these areas was blocked completely in preab-
sorption control studies.
Immunohistochemical and in situ hybridization controls
demonstrated high specificity of the OFQ antiserum and
the 35S-labeled prepro-OFQ riboprobe used in this study. A
detailed description of the distribution of prepro-OFQ
mRNA and OFQ peptide is presented below. Anatomic
descriptions and nomenclature are based on those de-
scribed for the rat CNS by Paxinos and Watson (1986). A
summary of OFQ mRNA and peptide distribution is pro-
vided in Table 1. An overview of OFQ mRNA expression in
the brain and spinal cord is presented in Figures 4 and 5.
Cortex
In situ hybridization. Prepro-OFQ mRNA expres-
sion is found throughout the rostral-to-caudal extent of the
neocortex. Cells containing OFQ mRNA are scattered
primarily in layers II, III, V, and VI, with the strongest
expression in layer VI. Prepro-OFQ mRNA-expressing
cells are most numerous in the frontal cortex (Fig. 2A),
Fig. 1. Brightfield photomicrographs demonstrating orphanin FQ
(OFQ)-containing fibers (arrows) and terminal-like structures (arrow-
heads) in noncolchicine-treated tissue. A: High-power image of the
striatum demonstrating the fine immunoreactive fibers found scat-
tered throughout this structure. B: High-power photomicrograph of
dense OFQ-containing fibers in the median eminence. C: High-power
photomicrograph of OFQ immunoreactivity in the posteroventral part
of the medial nucleus of the amygdala demonstrating immunolabeled
fibers and terminal-like structures in this region. For abbreviations,
see list. Scale bar 5 50 µm.
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Fig. 2. Darkfield autoradiograms of in situ hybridization controls.
A: mRNA expression obtained after hybridization with a 35S-labeled
cRNA (antisense strand) generated against the 58 portion of the
preproorphanin sequence in the frontal cortex (AS). B: mRNA expres-
sion is absent in an adjacent section hybridized with a 35S-labeled
mRNA (sense strand) generated against the same region of the
preproorphanin sequence (S). C: Photomicrograph of mRNA-express-
ing neurons in the rostral claustrum. D: Labeling is absent in an
adjacent section treated with RNase A prior to hybridization (R).
E: Antisense signal generated in the peripeduncular nucleus of the
mesencephalon. F: Labeling is absent in an adjacent section following
hybridization with sense strand. G: mRNA-expressing neurons in
laminae VIII and IX of the ventral horn of the cervical spinal cord. In
H, labeling is absent in an adjacent section that was treated with
RNase A prior to hybridization. Scale bar 5 200 µm in A–F, 100 µm in
G,H.
with mRNA expression in the temporal cortex weakest of
all regions. No mRNA expression is observed within the
corpus callosum.
Messenger RNA expression is also strong in other corti-
cal regions. Rostrally, moderate mRNA expression is seen
in medial, lateral, and ventral orbital cortices, primarily in
layer II. Expression levels are strongest in the rostral pole
of the orbital cortex, tapering off at caudal levels. In the
rostral agranular insular cortex, mRNA-containing neu-
rons are numerous and are found mostly in layers II, III,
and V. This mRNA expression becomes most intense in
caudal insular regions, with adjacent granular cortex
maintaining a more moderate distribution of prepro-OFQ-
containing neurons. In the rostral forebrain, mRNAexpres-
sion is strong in the prefrontal cortical regions. Messenger
RNA-containing neurons are numerous in the infralimbic
and dorsal peduncular cortical regions ventrally and in the
rostral cingulate cortex dorsally, mostly in layers II, III,
and V. Rostral cingulate expression is strongest in area 1,
but mRNA expression intensity is strongest in area 2
caudally, into the retrosplenial cortices. Messenger RNA
levels throughout the retrosplenial cortex remain heavy in
the agranular part, primarily in layers II and V rostral,
and in layers II and III caudal. In the rostral tenia tecta,
Fig. 3. Brightfield photomicrographs demonstrating immunohisto-
chemistry controls in colchicine-treated animals: Immunolabeling in
area CA1 of Ammon’s horn in the hippocampal formation after
incubation with primary OFQ antiserum (A) is absent in the same
region when incubated in primary antiserum after preabsorption with
25 mM OFQ peptide (B). Densely immunolabeled neurons within the
substantia nigra, pars reticulata (C) are unlabeled in adjacent control
tissue (D). Cell and fiber immunolabeling within the dorsal horn of the
spinal cord (E) also is blocked completely in adjacent control tissue (F).
For abbreviations, see list. Scale bar 5 75 µm in A,B, 200 µm in C–F.
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TABLE 1. Distribution of Orphanin FQ Peptide and mRNA
in the Rat Central Nervous System1
CNS region





Layer I 2 2 2
Layer II 1 1 111
Layer III 11 1 111
Layer IV 2 2 2
Layer V 1 1 11
Layer VI 11 1 111
Parietal
Layer I 2 2 2
Layer II 1 2 111
Layer III 1 2 11
Layer IV 2 2 2
Layer V 1 1 1
Layer VI 11 1 111
Temporal
Layer I 2 2 2
Layer II 2 1 1
Layer III 2 1 1
Layer IV 2 2 2
Layer V 2 1 1
Layer VI 1 1 11
Occipital
Layer I 2 2 2
Layer II 2 2 11
Layer III 2 2 11
Layer IV 2 2 2
Layer V 1 1 1
Layer VI 11 1 11
Other cortical regions
AI 1 2 111
cc 2 2 2
Cg 11 1 111
DP 2 2 1
Ent 2 2 111
GI 1 2 11
IL 1 2 11
LO 1 2 111
MO 2 2 11
Pir 1 11 11
RSA 11 1 111
RSG 11 1 11
TT 11 2 11
VO 11 2 111
Ventral forebrain
ac 2 2 2
AcbC 1 1111 11
AcbSh 1 11 1
AOD 2 2 2
AOL 2 2 1
AOM 2 2 11
AOP 11 1 1
AOV 1 2 11
FStr 2 111 2
HDB 1111 11 1111
ICj 2 2 2
SI 111 11 111
Tu 1 1 11
VDB 1 11 111
VP 1 111 11
Septum
df 2 2 2
Ld 2 2 2
LSD 111 11 11111
LSI 11 11 1111
LSV 1 111 111
MS 1 2 1
PLd 2 2 2
SHi 11 11 11
SHy 111 111 1111
Basal ganglia
B 111 11 11
Cl 11 2 111
CPu 1 11 1
Den 11 1 111
EP 11 11 11
GP 111 1 111
SNC 11 11 111
SNL 11 1 11
SNR 111 1 111
STh 1 1 1
VEn 11 2 11
Basal telencephalon
AMPO 1 1111 1
AVPO 111 111 1111
BSTl 11 1111 11
TABLE 1. (continued)
CNS region





BSTld 111 111 1111
BSTlj 1 11 1
BSTlp 111 111 1111
BSTlv 1 1111 111
BSTma 111 1111 11111
BSTmpl 1111 11 11111
BSTmpm 1111 11 11111
BSTmv 111 1111 1111
f 2 2 2
LOT 11 1 11
LPO 11 111 111
MCPO 111 1 111
MPA 11 1111 1111
MPO 111 1111 1111
Pe 1 111 1
st 1 11 2
Hypothalamus
AHA 11 1 111
Arc 111 111 111
DA 1 11 11
DM 11 111 111
LA 11 1 1
LH 111 1 11
LM 1111 11 11
ME 2 1111 2
ML 2 2 2
MM 2 2 2
MMn 11 111 1
mp 2 2 2
MTu 11 2 11
Pe 1 111 1
PeF 1 2 1
PH 11 2 111
Pin 2
Pit 2 2 2
PMD 11 111 111
PMV 11 111 11
PVNm 1 1 1
PVNp 11 11 11
RCh 111 1 1
SCh 2 2 2
SO 2 11 2
SOR 2 111 2
SuM 11 11 111
sumx 2 2 2
TC 11 11 11
Te 11 2 2
TM 11 1 11
TMC 1 2 1
VMH 1 111 2/1
Amygdala
AAA 2 1 1
ACo 1 1 1
AHiA 2 2 1
APir 2 2 2
BAOT 1 11 1
BL 1 1 11
BM 1 2 1
BSTIA 1 11 11
CeL 1 111 11
CeM 111 1111 1111
I 1 11 2
La 2 2 2
MeAD 11 111 11
MeAV 2 1 1
MePD 1111 1111 11111
MePV 1 111 111
opt 2 2 2
PLCo 2 2 2
PMCo 11 1 11
Hippocampal formation
CA1so 1 11 1
CA1sp 111 1 111
CA1sr 11 11 1
CA2so 1 2 2
CA2sp 11 2 11
CA2sr 2 2 1
CA3sl 111 11 111
CA3so 2 1 2/1
CA3sp 11 1 11
CA3sr 2 1 1
DGgr 11 1 111
DGhi 2 2 2
DGmo 1 11 1
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TABLE 1. (continued)
CNS region





DGpo 1 1 1
IG 111 1 111
PaS 1 2 11
PrS 1 2 1
S 111 1 111
SFO 1 11 11
SHi 11 11 11
Thalamus
AD 2 11 2
AM 2 2 2
AV 2 1 11
CL 2 2 2
CM 2 2 2
F 2 2 2
IAD 2 111 2
LD 2 2 1
LGN 2 2 1
LHb 2 11 11
LP 2 2 2
MD 2 2 1
MGN 2 2 2
MHb 11 111 1
mt 2 2 2
PC 2 11 2
PLi 1 2 11
Po 1 2 11
PR 2 2 1
PrC 11 111 11
PT 2 111 111
PVA 1 111 11
PVP 2 1 11
Re 2 1 1
Rh 2 1 2
RI 2 2 1
Rt 1111 11 11111
SG 111 2 11
SPFPC 11 111 111
SubG 2 2 11
VL 2 2 2
VM 2 2 2
VPL 2 2 2
VPM 2 2 2
ZI 11 11 111
Mesencephalon
APT 111 11 11
APTD 11 11 11
APTV 111 1 111
ATg 1 1 2
bic 2 2 2
BIC 2 11 2
CG 1111 111 1111
CGD 1 1 11
cic 2 2 2
CIC 1 2 2
CLi (B8) 11 1 11
CnF 2 2 2
cp 2 2 2
csc 2 2 2
ctg 2 2 2
DCIC 1 1 1
Dk 1111 11 11111
dlf 2 2 2
DLL 2 2 2
DpMe 1 1 11
DR (B7) 11 11 11
DTg 111 1 1111
ECIC 11 1 111
EW 2 2 2
fr 2 2 2
lfp 2 2 2
ILL 2 2 2
IMLF 11 1 111
InCo 2 2 2
IPC 1 1 11
IPD 11 111 1111
IPL 2 1 111
IPR 111 1 111
LC 11 11 111
LDTg 111 11 111
LGN 2 2 1
ll 2 2 2
MA3 2 2 2
MCPC 1 2 11
Me5 2 2 2
MGN 2 2 2
TABLE 1. (continued)
CNS region





MiTg 2 2 2
ml 2 11 2
MnR (B8) 111 1 11
mp 2 2 2
OPT 11 2 1
OT 11 1 11
Pa4 2 2 2
PBG 2 2 2
pc 2 2 2
PCom 111 2 111
PL 1 2 2
PLi 1 2 11
PMR 11 2 1
Pn 2 1 2
PN 111 1 1111
PnO 1 11 11
PP 111 11 1111
PPT 11 2 11
PPTg 11 1 111
PR 2 2 2
Rbd 2 2 2
RLi 11 1 11
RMC 1 1 11
RPC 2 1 1
RPO 1 2 2
RR 11 2 1
RRF 11 1 11
rs 2 2 2
RtTg 2 2 2
SC(DpG) 2 2 1
SC(DpWh) 2 2 2
SC(InG) 111 1 111
SC(InWh) 2 2 2
SC(Op) 11 1 11
SC(SuG) 1 1 1
SC(Zo) 2 1 2
scp 2 2 2
SG 11 2 111
SNC 11 1 111
SNL 11 1 11
SNR 111 11 111
sp5 2 2 2
SPTg 2 2 2
Su3 11 1 11
tz 2 2 2
Tz 11 2 111
VLL 2 2 2
VLTg 2 2 2
VTA 111 11 111
VTg 1 1 11
ZI 11 11 111
Cerebellum
Lobules 1 2 1
IntA 2 2 2
IntDL 2 2 2
IntDM 2 2 2
IntP 2 2 2
Lat 2 2 2
LatPC 2 2 2
Med 111 11 11
MedDL 11 11 11
Metencephalon
6 2 2 2
6n 2 2 2
7 2 2 2
7n 2 2 2
8n 2 2 2
A5 11 2 11
A7 2 2 2
CGPn 11 1 11
CPO 2 1 2
DC 11 1 1
DMTg 1 2 11
DPO 1 2 11
DR (B6) 11 11 11
DTg 11 2 11
Gi 1 2 11
GiA 11 2 11
GiV 111 2 111
Gr 2 2 2
icp 2 2 2
KF 2 2 2
LC 11 11 111
LDTg 1 2 11
LPB 11 1 111
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scattered neurons expressing OFQ mRNA emerge in layer
III at the level of the rostral accumbens. Caudally, more
intense labeling is observed in its dorsal part in layers II
and III. The piriform cortex maintains persistent cell
labeling throughout its rostral-to-caudal extent. Messen-
ger RNA levels in this cortical region are light to moderate,
primarily in layer III, with occasional scattered neurons in
layer II. In the entorhinal cortex, mRNA expression is
moderate throughout but is observed mostly in layers II
and III.
Immunohistochemistry. Moderately immunostained
cells are scattered throughout the rostral-to-caudal extent
of both the neocortex and the allocortex. Fiber labeling is
minimal, with occasional fibers noted primarily in layers V
and VI in untreated animals. These fibers are seen in all
cortical regions and are sparse. Fibers in layer VI main-
tain a parallel orientation, whereas those in other layers
maintain a perpendicular orientation. Immunolabeling in
the frontal cortex is light to moderate to its caudal extent,
with most immunolabeled neurons within layers II, III,
and VI rostral and with occasional scattered neurons
noted in layer V caudally. Rostral parietal regions demon-
strate sparse immunolabeling, but OFQ-containing neu-
rons are slightly more numerous and are stained more
moderately in its middle-to-caudal regions. These peri-
karya are scattered mostly in layers II, III, V, and VI. In
the temporal cortex, the weakest OFQ neocortical immuno-
labeling is observed. Perikarya are observed occasionally
in layer VI and are stained moderately. Occipital immuno-
labeling is confined to scattered, moderately labeled neu-
rons in layers V and VI, primarily in its dorsal part.









LPGi 11 2 1111
LRt 1 2 11
LSO 1 11 11
LVe 11 1 111
LVPO 11 1 11
mlf 2 2 2
MnR (B5) 111 1 11
Mo5 2 2 2
MPB 2 2 2
MSO 2 2 2
MVeV 11 1 11
MVe 11 11 11
MVPO 11 1 111
Pa5 1 2 11
PCRt 2 11 1
PDTg 1 2 111
PnC 11 1 11
PnR 11 1 111
PnV 11 1 1
PPTg 111 2 111
Pr5 2 2 2
py 2 2 2
RMg 111 11 1111
RPa (B1) 11 1 11
RPO 1 11 11
Sp5O 2 1 1
SPO 11 11 11
SpVe 1 1 11
SubC 2 2 2
SuVe 111 1 11
Tz 11 2 111
VCA 2 2 2
VCP 2 2 2
Mylencephalon
9n 2 2 2
10 2 2 2
12 2 2 2
A5 11 2 11
A7 2 2 2
Amb 111 11 1111
C1 2 2 2
C2 2 2 2
C3 2 2 2
CI 11 2 111
Cu 2 2 2
DMSp5 111 111 11111
DPGi 1 2 1
ECu 2 2 1
Gr 2 2 2
IOA 1 2 11
IOB 2 2 11
IOD 111 11 11
IODM 2 2 2
IOM 2 2 2
IOPr 111 1 111
IRt 11 2 111
LVe 11 1 111
MdD 11 2 11
MdV 11 2 11
mlf 2 2 2
MVeV 2 2 2
MVe 11 1 11
Pa5 1 2 11
PrH 1111 111 1111
py 2 2 2
RAmb 111 2 11111
RMg (B3) 111 11 1111
ROb (B2) 1 1 11
SGe 11 111 111
sol 2 2 2
Sol 11 11 1111
SolC 111 11 11
SolL 111 111 111
SolM 11 111 111
Sp5C 111 1111 11111
Sp5I 2 111 1
SpVe 11 1 1
SuVe 11 1 11
Tz 111 2 111
VCA 2 2 2
VCP 2 2 2
Spinal cord
Cervical
I 2 11 2
II 11 1111 1111
TABLE 1. (continued)
CNS region





III 11 111 111
IV 2 111 2
V 2 1 1
VI 2 1 1
VII 1 1 11
VIII 1 1 1
IX 11 2 11
X 11 111 111
Thoracic
I 2 1 2
II 11 111 1111
III 2 11 111
IV 2 11 2
V 2 11 1
VII 2 11 2
VIII 11 1
IX 1 2 11
X 11 111 11
cu 2 2
dcs 2 2 2
DRG 1
gr 2 2 2
IML 2 2 2
IMM 1 2 111
LatC 111 111 1
lfu 2 2 2
LSp 11 111 2
vfu 2 2 2
Distribution of orphanin FQ immunoreactivity and preproorphanin mRNA in the
central nervous system (CNS) of the adult male rat. Degree of immunoreactivity and
mRNAexpression was graded arbitrarily based on density and intensity of immunostain-
ing, and intensity of microscopic mRNA expression was assessed based on emulsion-
dipped sections. F/T, fibers/terminals. Gradations used were 11111, highest signal
intensity (used for mRNA expression); 1111, intense; 111, moderate; 11, light to
moderate; 1, light or sparse; 2, undetectable. For abbreviations, see list.
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Fig. 4. A–J: Distribution of prepro-OFQ mRNA in the rat brain at representative coronal sections
through the forebrain. For abbreviations, see list. Scale bar 5 500 µm.
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Scattered, lightly labeled cells are noted in the ventral
orbital cortex, with moderately labeled immunoreactive
cells noted in layers I and II of the dorsal peduncular and
infralimbic cortices. Immunolabeling in the insular cortex
is confined to scattered, lightly labeled neurons in layers II
and III, mostly in its granular part. Immunolabeled neu-
rons are observed throughout the tenia tecta, mostly in
layer II (Fig. 6B), and in the indusium griseum, where
Fig. 5. A–H: Distribution of prepro-OFQ mRNA in the rat brain at representative coronal sections
through the brainstem and spinal cord. For abbreviations, see list. Scale bar 5 500 µm.
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darkly stained cells are seen throughout its rostral-to-
caudal extent. In the piriform cortex, scattered, moder-
ately stained cells are dispersed throughout layer III, with
a moderate network of fibers and puncta observed in layer
III in untreated animals (Fig. 6A). No immunolabeling is
observed in layer I. Lightly immunolabeled neurons and
minimal fibers are observed in the amygdalopiriform
transition area, and the entorhinal and perirhinal cortices
exhibit no immunolabeling. OFQ-containing cells are dark
and are most prominent in layers II and III throughout the
cingulate cortex, with darkly immunolabeled neurons
noted in layer VI in its caudal extent. This pattern persists
into the retrosplenial cortex, where darkly stained cells
are observed in its agranular and granular parts to its
caudal extent.
Ventral forebrain
In situ hybridization. Messenger RNA expression is
weak in the rostral anterior olfactory nucleus, particularly
in its lateral and dorsal parts. More caudally, mRNA levels
increase, with scattered mRNA-expressing neurons ob-
served mostly in the medial, lateral, and posterior parts.
Caudally, mRNA expression in the ventral division is the
strongest of the entire anterior olfactory nucleus. No
immunolabeled neurons are observed in the rostral pole of
nucleus accumbens. As the accumbens differentiates into
core and shell components, only scattered OFQ-containing
neurons are observed in the shell throughout its rostral-to-
caudal extent. Throughout the accumbens core, mRNA
expression is very light, with mRNA-containing neurons
localized to the lateral part of the nucleus and extending
into the substantia innominata. Medial to the accumbens
shell, the major island of Calleja is devoid of mRNA
expression. Throughout the ventral forebrain, the islands
of Calleja and fundus striati contain no OFQ mRNA
expression. Orphanin-containing neurons are lightly scat-
tered in the medial ventral pallidum and are more numer-
ous in its lateral aspect. Messenger RNA expression in the
olfactory tubercle is moderate, with neurons scattered
primarily throughout layer III. Moderate numbers of
OFQ-containing neurons are observed in the vertical limb
of the diagonal band of Broca (Fig. 9B). Heavy mRNA
expression is observed in the horizontal limb to its caudal
boundary, where a cluster of prepro-OFQ-containing neu-
rons is present dorsal to the supraoptic nucleus in the
rostral hypothalamus. No mRNA expression is present in
the anterior commissure at any level.
Immunohistochemistry. Immunolabeling in the ante-
rior olfactory nucleus is confined to sparse, lightly stained
neurons ventrally and to more numerous neurons in its
posterior division, where cells are stained more moder-
ately. In untreated animals, diffuse fibers and puncta are
observed in the more caudal aspect of this nucleus extend-
ing into the rostral pole of the accumbens. Immunolabeling
in the rostral pole of the nucleus accumbens is limited to
diffuse, fine, moderately labeled fibers that are observed
Fig. 6. Brightfield photomicrographs of OFQ immunolabeling in
rostral forebrain structures. A: Fiber and neuronal immunolabeling
within layer III of the piriform cortex. B: Photomicrograph illustrating
OFQ-containing neurons within layer II of the tenia tecta. C,D: Low-
and high-power images, respectively, of immunolabeled fibers in the
core of nucleus accumbens in untreated animals. For abbreviations,
see list. Scale bar 5 100 µm in A–C, 50 µm in D.
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best in untreated animals. As the shell emerges, it con-
tains scattered fibers and puncta with occasional darkly
stained cells. Fine, immunoreactive fibers extend medially
into the vertical limb of the diagonal band of Broca and
caudally as a continuum with the ventral division of the
bed nucleus of the stria terminalis. The accumbens core
contains only occasional lightly stained neurons, whereas
diffuse fibers are spread throughout this nucleus. Fiber
immunolabeling intensifies caudally in its dorsal part,
adjacent to the striatum (Fig. 6C,D), and extends ventrally
with less intensity into the ventral pallidum. In the
ventral pallidum, lightly immunolabeled neurons are scat-
tered throughout the region, with a prominent fiber plexus
observed to its caudal extent. A similar network of dense
fibers and puncta is observed in the fundus striati with no
immunoreactive neurons. This pattern of fiber immunola-
beling, which is observed best in untreated animals, is
similar to that seen in the ventral pallidum.
Several moderately stained neurons are found in layers
II and III of the olfactory tubercle, with dark fibers and
puncta distributed primarily in layer II. No immunostain-
ing is observed in the islands of Calleja. The vertical limb
of the diagonal band of Broca contains moderately immuno-
labeled fibers and puncta but only occasional lightly
immunolabeled neurons. At the emergence of the horizon-
tal limb, darkly labeled OFQ-containing neurons appear
and remain to its caudal pole as a cluster of densely
stained neurons ventrolateral to the preoptic area. Adja-
cent to the fundus striati caudally, several large, darkly
stained, OFQ-containing neurons and fibers are observed
in the substantia innominata. Scattered fibers present in
the substantia innominata extend dorsally into the basal
nucleus of Meynert, where large, moderately stained neu-
rons are observed also in its caudal region. The anterior
commissure is devoid of immunolabeling.
Septum
In situ hybridization. OFQ mRNA expression in this
entire region is very strong (Figs. 7A, 9A). Initially, light
OFQ expression is observed in the most rostral pole of the
lateral septum in its ventral and intermediate parts. At
this level, the septohippocampal nucleus has moderate
Fig. 7. Photomicrographs of mRNA expression and immunolabel-
ing in the lateral septal nucleus. A: Low-power photomicrograph of
mRNA expression in the dorsal, intermediate, and ventral divisions of
the lateral septum. B: High-power photomicrograph of the dorsal
lateral septum demonstrating numerous mRNA-containing neurons
within this region. C: Brightfield photomicrograph of immunolabeling
in the lateral septum in a colchicine-treated animal. For abbrevia-
tions, see list. Scale bar 5 800 µm in A, 200 µm in B, 100 µm in C.
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mRNA expression, which persists to its caudal extent. In
the lateral septal nucleus, light OFQ expression is seen
initially in the anterior portion of its ventral part. At the
emergence of the dorsal lateral septum, mRNA expression
becomes very intense, filling this division throughout its
extent (Fig. 7B). The intermediate lateral septum also is
labeled heavily but not as intensely as the dorsal part. The
ventral part contains moderate mRNA expression. Scat-
tered OFQ mRNA-containing neurons in the ventral lat-
eral septum are observed primarily along the dorsal aspect
of the accumbens shell, persisting caudally to the bed
nucleus of the stria terminalis. At this level, intense
mRNA expression is observed intensifying and stretching
out from the lateral septal region into the septohypotha-
lamic nucleus (Fig. 9A). The medial septal nucleus has
scattered OFQ-containing cells. No mRNA expression is
observed in the lambdoid zone, the paralambdoid septal
nucleus, or the dorsal fornix.
Immunohistochemistry. In contrast to the intense
mRNA expression observed in this region, immunolabel-
ing in the lateral septum is modest (Fig. 7C). A plexus of
scattered fibers and terminals and numerous darkly
stained cells resides in the dorsolateral portion of this
nucleus, remaining consistently immunolabeled through-
out. Moderately labeled OFQ-containing neurons in the
intermediate lateral septal nucleus reside mostly along its
lateral boundary, with more numerous immunolabeled
neurons in the ventral part. In untreated animals, fiber
and terminal staining in the intermediate division is
moderate to intense, and the ventral lateral septum con-
tains scattered, light neurons among a moderate fiber and
terminal plexus located primarily along the ventrolateral
border. Scattered, lightly labeled neurons are observed in
the medial septum, where fiber labeling is negligible. No
immunolabeling is noted in the lambdoid septal zone or
the paralambdoid septal nucleus. The septohippocampal
region contains a moderate number of densely stained
neurons and fibers. Immunolabeling in the septohypotha-
lamic nucleus is prominent, with moderately stained fibers
and dark cells extending ventral to the bed nucleus of the
stria terminalis. The dorsal fornix is devoid of immunola-
beling.
Basal ganglia
In situ hybridization. In the rostral forebrain, promi-
nent numbers of OFQ-containing neurons are observed in
the claustrum scattered throughout the nucleus (Fig. 2C).
At the emergence of the striatum, mRNA-containing neu-
rons in the claustrum become much more numerous, with
light-to-moderate mRNA expression extending ventrally
into the dorsal and ventral endopiriform nuclei. The
striatum contains little prepro-OFQ mRNA expression.
Only scattered OFQ-containing neurons are identified
throughout this nucleus, with mRNA-containing neurons
more numerous in its mediodorsal part. Messenger RNA
expression is intense throughout the globus pallidus.
Neurons within this structure are not dense in number,
but intensity of mRNA expression is strong, and labeled
neurons are large. Near the caudal striatum, the basal
nucleus of Meynert contains a moderate number of neu-
rons expressing OFQ mRNA. The adjacent entopeduncu-
lar nucleus has numerous large, mRNA-expressing neu-
rons, mostly in its ventromedial aspect. At the caudal
extent of the entopeduncular nucleus, the subthalamic
nucleus contains scattered, light mRNA expression.
Caudal to the subthalamic nucleus, preproorphanin
mRNA is very prominent in the substantia nigra. In its
rostral pole, scattered neurons are present in the pars
reticulata. From its midrostral to midcaudal region, the
pars reticulata contains heavy mRNA expression (Fig. 8C),
falling off somewhat caudally, with scattered OFQ-
containing neurons mostly in its dorsal part. The pars
compacta contains lightly scattered, large, mRNA-contain-
ing neurons in its rostral portion, with mRNA expression
becoming quite intense into the caudal half of this region
(Fig. 8D) and persisting into the pars lateralis.
Immunohistochemistry. In the rostral forebrain, mod-
erately labeled neurons and occasional scattered fibers are
noted in the most rostral extent of the claustrum. This
pattern persists throughout the nucleus. The dorsal endop-
iriform nucleus contains scattered, moderately labeled
neurons and fibers, with most neurons residing medially.
In the ventral endopiriform nucleus, immunolabeling con-
sists of scattered neurons with no fibers. The striatum
contains sparse, darkly stained fibers noted throughout its
rostral-to-caudal extent. These diffuse fibers are observed
equally in both colchicine-treated and untreated animals
(Fig. 1A). Although these fibers can be seen in all regions of
the striatum, there is a predominance in its ventromedial
aspect. Occasional small, lightly immunolabeled neurons
are observed but are very few in number. At the emergence
of the globus pallidus, darkly immunolabeled neurons
appear and remain throughout its extent (Fig. 8A). These
neurons, although they are not numerous, are large and
intensely stained. Medial to the globus pallidus at more
caudal levels, large, darkly labeled neurons are observed
throughout the basal nucleus of Meynert (Fig. 8B). There
is moderate fiber staining in this structure, with lightly
labeled puncta extending into the substantia innominata.
The entopeduncular nucleus contains scattered, darkly
immunolabeled neurons with sparse fibers and terminals.
Immediately caudal to the entopeduncular nucleus,
sparse, lightly labeled fibers and neurons are observed in
the subthalamic nucleus, confined primarily to its ventro-
medial part. The pars reticulata of the substantia nigra
emerges with numerous, moderately labeled perikarya
and fibers that are most numerous in its ventromedial part
and that extend dorsally in caudal regions (Fig. 3C).
Although the pars compacta has significantly fewer peri-
karya than are seen in the pars reticulata, neurons are
intensely immunolabeled. Caudally, the darkly stained,
large neurons in the pars compacta extend dorsolaterally
into the pars lateralis.
Basal telencephalon
In situ hybridization. Within the forebrain, mRNA
expression is highest within the basal telencephalon (Fig.
9A). In the rostral bed nucleus of the stria terminalis,
mRNA expression is observed throughout the entire me-
dial and lateral parts. Heavy mRNA levels are seen
generally throughout the lateral division, with very light
mRNA expression observed in its juxtacapsular part and
with heavy expression in its dorsal and ventral parts. The
medial division has a moderate-to-strong mRNA expres-
sion in its ventral part (Fig. 9B), increasing dramatically
in its caudal aspect. Intensity of mRNA expression in the
posterolateral part of the medial division is the strongest
of the entire bed nucleus of the stria terminalis. Intense
mRNA expression persists to the caudal pole of this
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nuclear complex, surrounding the fornix in the anterior
hypothalamus. In this region, scattered, mRNA-express-
ing neurons extend medially from this nucleus into the
region of the paraventricular nucleus of the hypothala-
mus. No prepro-OFQ mRNA expression is observed in the
fornix or the stria terminalis.
In the preoptic region, heavy mRNA expression is seen
in the anteroventral preoptic nucleus, contrasting sharply
with that of the anteromedial preoptic nucleus, in which
mRNA levels are much lighter. The adjacent medial preop-
tic area is filled with mRNA-containing neurons through-
out its rostral-to-caudal extent (Fig. 9E), with expression
heaviest in its dorsal part rostrally and in the lateral
aspect of this region more caudally. This expression pat-
tern extends into the lateral preoptic area, where it
remains strong. The medial preoptic nucleus contains a
dense accumulation of cells expressing OFQ mRNA (Fig.
9E). Just caudal to the horizontal limb of the diagonal
band, moderate mRNA levels are observed in neurons
within the magnocellular preoptic nucleus. In the caudal
basal telencephalon, the nucleus of the lateral olfactory
tract contains scattered neurons expressing mRNA. These
OFQ-containing neurons are light to moderate in number
and are confined mostly to layer II, with an occasional
neuron observed in layer III. No OFQ mRNA expression is
seen in the lateral olfactory tract.
Immunohistochemistry. Paralleling its mRNA ex-
pression pattern, immunolabeling in this region is quite
intense. In the rostral bed nucleus of the stria terminalis,
dense fibers, terminals, and immunolabeled neurons ex-
tend from the septohypothalamic nucleus and fill the
anterior and ventral parts of the medial division. Farther
caudally, a plexus of neurons, fibers, and puncta fill the
posteromedial part of the medial division and most of the
posterolateral part (Fig. 9C,D). This dense, immunola-
beled plexus lies adjacent to the lateral ventricle and
spreads ventrally toward the preoptic area. In the caudal
posterolateral part of the medial division, a unique distri-
bution pattern emerges. At the level of the anterior
hypothalamus, numerous darkly stained neurons sur-
round the fornix. This cell group extends medially as a
continuum to the lateral boundary of the magnocellular
part of the paraventricular nucleus of the hypothalamus,
remaining outside of its boundaries and extending into the
lateral hypothalamic area. Fiber and terminal labeling in
the lateral subdivision is slightly more intense than in the
medial subdivision at rostral levels, but drops off in
posterior regions. The juxtacapsular part of the lateral
subdivision contains only occasional cell bodies with light-
to-moderate fiber and terminal staining (Fig. 9C). Peri-
karya are not observed in the posterior part of the lateral
division, and fiber labeling drops off dramatically to its
caudal extent, where immunolabeling in the medial divi-
sion is most intense. Fiber staining is prominent in the
stria terminalis, particularly dorsally, adjacent to the
lateral ventricle. Occasional darkly stained neurons are
Fig. 8. Photomicrographs of mRNA expression and immunolabel-
ing in basal ganglia-related structures. A: Brightfield photomicro-
graph of OFQ immunoreactivity in the globus pallidus demonstrating
OFQ-immunoreactive fibers and cell bodies. B: Cell and fiber immuno-
labeling in the basal nucleus of Meynert (colchicine treated). C,D: In
the substantia nigra, orphanin mRNA expression is heavy in midros-
tral to caudal levels of the pars reticulata (C) and in the caudal part of
the pars compacta (D). For abbreviations, see list. Scale bar 5 100 µm
in A,B,D, 200 µm in C.
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present in this structure as well. The fornix is devoid of
immunolabeling.
The medial preoptic area contains scattered, darkly
stained neurons and moderate-to-heavy fibers throughout
its extent (Fig. 9F). Fewer immunolabeled neurons are
seen in the medial preoptic nucleus and the magnocellular
preoptic nucleus, and only scattered, lightly stained cells
are seen in the anteromedial preoptic nucleus. A cluster of
darkly stained neurons is observed in the anteroventral
preoptic nucleus, continuing laterally with the caudal part
of the horizontal limb of the diagonal band. Fiber and
terminal labeling is very strong in the anteroventral and
anteromedial nuclei and throughout the medial preoptic
nucleus. Immunolabeled fibers and terminals are sparse in
the magnocellular preoptic nucleus, which contains a
cluster of moderately immunolabeled neurons. The lateral
Fig. 9. Photomicrographs of OFQ mRNA and protein expression in
the medial preoptic area and the bed nucleus of the stria terminalis.
A: Low-power image of the rostral basal telencephalon demonstrating
strong mRNA signal in the lateral septum, bed nucleus of the stria
terminalis, and medial preoptic area. B: High-power photomicrograph
demonstrating OFQ-containing neurons in the ventral part of the
medial bed nucleus of the stria terminalis. Several neurons with
robust OFQ mRNA signal in the ventral diagonal band are also
present. Dashed line outlines the boundary of the anterior commis-
sure. C: OFQ immunoreactivity in the dorsal part of the lateral bed
nucleus of the stria terminalis, the juxtacapsular part of the lateral
division, and the anterior part of the medial division (colchicine
treated). D: OFQ-immunoreactive fibers and neurons in the posterolat-
eral medial division of the bed nucleus (colchicine treated). E: Orpha-
nin expression in the midpreoptic region demonstrates moderate
mRNA signal intensity, with a cluster of intense mRNA signal in the
medial preoptic nucleus. F: OFQ-containing fibers and light cells in
the medial preoptic area and the medial preoptic nucleus (untreated).
For abbreviations, see list. Scale bar 5 850 µm in A, 200 µm in B,F, 100
µm in C, 150 µm in D, 400 µm in E.
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preoptic area contains scattered, darkly stained neurons
among moderate fibers and light terminal labeling, mostly
in its medial aspect. Ventrally in this region, the nucleus of
the lateral olfactory tract contains moderate numbers of
lightly stained cells that are confined to layers II and III.
Sparsely immunolabeled fibers and no puncta are ob-
served in this nucleus.
Hypothalamus
In situ hybridization. In analyzing the nuclei of the
hypothalamus by regions, based on a parcellation scheme
that has been described previously by Swanson (1992), it
becomes evident that the majority of OFQ in the hypotha-
lamic region lies primarily in the medial zone. In the
ventral hypothalamus, the suprachiasmatic and supraop-
tic nuclei are devoid of mRNA expression. Farther cau-
dally, scattered cells are observed in the tuber cinereum,
with strong expression observed within the medial tuberal
nucleus and dorsal into the magnocellular part of the
lateral hypothalamus. Occasional scattered neurons con-
taining OFQ mRNA are noted within the retrochiasmatic
area, just caudal to the suprachiasmatic nucleus. Orpha-
nin mRNA expression is more moderate in the arcuate
nucleus, persisting throughout its rostral-to-caudal ex-
tent, with heaviest expression in more ventral regions. No
mRNA expression is seen in the median eminence. The
ventromedial hypothalamic nucleus is devoid of mRNA
expression, with only an occasional OFQ-containing neu-
ron noted in the shell region.
In the dorsal region of the hypothalamus, there is a
decrease in mRNA levels in the transition from the poste-
rior bed nucleus of the stria terminalis into the anterior
and lateral hypothalamic areas rostrally, where expres-
sion remains moderately strong. An occasional OFQ-
containing neuron is observed in the lateroanterior hypo-
thalamic area. A moderate cluster of mRNA-expressing
cells is observed in the parvocellular part of the paraven-
tricular nucleus. Although several orphanin-containing
neurons are observed at the lateral border of this nucleus,
the magnocellular part itself has only occasional, scattered
mRNA-expressing cells. Caudal to the paraventricular
nucleus, cells expressing mRNA are lightly scattered in
the dorsal hypothalamic area, moderately scattered in the
tuberal magnocellular nucleus, and numerous in the dorso-
medial hypothalamic nucleus. Lateral to the dorsal hypo-
thalamic area, the perifornical nucleus contains only scat-
tered neurons expressing OFQ mRNA, with intensity
increasing into the posterior hypothalamus. At the mid-
line, the periventricular nucleus contains scattered mRNA-
expressing neurons, persisting to its caudal extent. There
is no mRNA expression detected in the terete hypotha-
lamic nucleus.
In the mammillary region, OFQ mRNA expression in the
ventral premammillary nucleus is moderate and increases
into the dorsal premammillary region. The supramammil-
lary (Fig. 11A) and lateral mammillary nuclei contain
moderate mRNA expression throughout their rostral-to-
caudal extents. In contrast, the medial mammillary nucleus
has very low mRNA levels and is devoid of mRNA expres-
sion in its lateral and medial divisions. The median
division of the medial mammillary nucleus contains only
lightly scattered mRNA-expressing cells. The mammillary
peduncle and supramammillary decussation are devoid of
mRNA expression. The pituitary (Fig. 11C) and pineal
(Fig. 11D) glands also are devoid of OFQ mRNA expres-
sion.
Immunohistochemistry. A cluster of large, darkly
stained neurons fills a region just lateral to the paraven-
tricular nucleus. These large, OFQ-containing neurons
extend laterally and surround the fornix in the posterolat-
eral part of the medial division of the bed nucleus of the
stria terminalis (Fig. 10C). The parvocellular part of the
paraventricular nucleus contains a modest number of
lightly stained neurons and fibers, mostly in its medial
aspect, adjacent to the third ventricle. Scattered, darkly
stained fibers and occasional neurons are present also
within the magnocellular part of this nucleus (Fig. 10C).
The lateroanterior hypothalamic nucleus, lateral hypotha-
lamic area, and anterior hypothalamic area contain moder-
ate numbers of large, OFQ-containing neurons. Caudally,
this cell cluster extends into the tuber cinereum. In all of
these regions, sparse, lightly stained fibers are present,
except for the tuber cinereum, where moderate fiber
staining is observed in untreated animals. The supraoptic
and retrochiasmatic supraoptic nuclei contain no immuno-
labeled neurons, but both regions contain darkly immuno-
labeled fibers throughout their rostrocaudal extent. No
immunolabeling is noted in the suprachiasmatic nucleus.
Caudally, the retrochiasmatic area contains numerous
darkly labeled neurons and fibers.
Throughout the rostral half of the hypothalamus, the
periventricular nucleus contains sparse, moderately
stained neurons immediately adjacent to the third ven-
tricle, with moderate fiber and terminal labeling. This
fiber and terminal staining extends ventrally at its caudal
pole into the arcuate region. The arcuate nucleus contains
moderately stained cells and fibers, with numerous puncta
throughout its rostral-to-caudal extent (Fig. 10A,B). Orpha-
nin-containing neurons in this nucleus are more numerous
in its dorsomedial part, and fibers within the arcuate
primarily maintain a dorsal-to-ventral orientation. The
median eminence contains an intense immunolabeled
fiber plexus. Large, densely stained fibers fill the more
medial aspect of the median eminence in its rostral part.
In the middle to caudal regions, median eminence fibers
are labeled more lightly in its medial aspect and are
labeled intensely in the lateral aspects (Figs. 1B, 10A,B).
Lateral to the arcuate nucleus, lightly stained neurons
are present only occasionally in the ventromedial hypotha-
lamic nucleus. In untreated animals, moderate fibers and
terminals are localized diffusely throughout the nucleus.
Farther lateral, lightly immunolabeled neurons are ob-
served in the medial tuberal nucleus, where no fiber or
terminal labeling is noted. Moderately stained cells and
fibers also are scattered in the dorsal hypothalamic area
and the dorsomedial hypothalamic nucleus. Immunostain-
ing in this region extends laterally into the perifornical
nucleus and persists caudally as lightly stained neurons in
the posterior hypothalamus. Moderately labeled neurons
are observed in the terete hypothalamic and tuberomam-
millary nuclei, and lightly labeled neurons are observed in
the tuberal magnocellular nucleus.
In the mammillary region, moderate-to-heavy fiber and
terminal labeling is present in the ventral and dorsal
premammillary nuclei, with only scattered, lightly stained
neurons observed. The medial mammillary nucleus con-
tains light-to-moderate cell and fiber immunolabeling in
its median division, whereas its medial and lateral divi-
sions are devoid of staining . Neuronal labeling is most
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pronounced in the lateral mammillary nucleus, which
contains a dense plexus of darkly stained fibers and cells
throughout (Fig. 10D). Moderate cell staining and strong
fiber and terminal staining is observed in the supramam-
millary nucleus (Fig. 11B). The mammillary peduncle and
supramammillary decussation are devoid of immunolabel-
ing in this region.
Amygdala
In situ hybridization. Orphanin mRNA expression
in the amygdaloid complex is relatively sparse in most
nuclei, except for the central and medial amygdaloid
nuclei, which contain intense OFQ mRNA expression (Fig
12A,C). Rostrally, the anterior amygdaloid area contains
occasional labeled neurons, particularly in its dorsal re-
gion. At the emergence of the central nucleus, scattered
orphanin-containing neurons are observed in the lateral
division, with the majority of mRNA expression confined to
the medial division more caudally. This mRNA expression
is moderate to heavy within the medial part of the central
nucleus to its caudal extent (Fig. 12C). Light mRNA
expression is observed in the basolateral and basomedial
nuclei, increasing in the intraamygdaloid division of the
bed nucleus of the stria terminalis. No mRNA expression is
observed in the intercalated or lateral amygdaloid nuclei.
The medial nucleus has moderate expression rostrally in
its anterodorsal part, with minimal expression in the
anteroventral division. This sparse distribution extends
ventrally into the bed nucleus of the accessory olfactory
tract. In the caudal one-third of the medial nucleus, mRNA
expression increases dramatically. The posteroventral part
of the nucleus contains moderate numbers of scattered
neurons expressing orphanin mRNA, whereas the pos-
terodorsal nucleus is filled completely with positive neu-
rons (Fig. 12A). This intensity increases into the caudal
pole of the medial nucleus, where the posterodorsal divi-
sion is packed with OFQ-containing neurons. Just caudal
to the medial nucleus, the amygdalohippocampal area
contains only scattered neurons with light mRNA levels.
Messenger mRNA levels in the anterior cortical amygda-
loid nucleus are very light, and this pattern persists
caudally into the posterior cortical nucleus. The posterome-
dial cortical nucleus contains light-to-moderate mRNA
expression. The posterolateral cortical amygdaloid nucleus
and the amygdalopiriform transition area have no mRNA
expression.
Immunohistochemistry. OFQ peptide expression at
the emergence of the amygdaloid region is very sparse,
with a scattering of fibers and puncta and with no immuno-
labeled neurons in the anterior amygdaloid area. A moder-
ate density of fibers and puncta reside in the rostral
intercalated amygdaloid nuclei adjacent to the central
nucleus; then, immunolabeling falls off dramatically, with
Fig. 10. Brightfield photomicrographs of orphanin immunoreactiv-
ity in the hypothalamus of colchicine-treated animals. A,B: Photomi-
crographs of rostral and caudal levels of the arcuate nucleus and
median eminence. Note orphanin-containing median eminence fibers
located medially at rostral levels and laterally at caudal levels.
C: Orphanin immunolabeling in the paraventricular nucleus demon-
strating labeled parvocellular neurons medially with scattered immu-
nolabeled neurons in the magnocellular part and darkly labeled
neurons just lateral to this nucleus. Dashed line outlines the boundary
of the paraventricular nucleus at that level. D: Immunolabeling in the
lateral mammillary nucleus. For abbreviations, see list. Scale bar 5
200 µm in A,B,D, 145 µm in C.
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only sparse terminal staining in the more caudal nuclei.
The central nucleus contains moderate-to-heavy fiber stain-
ing in its rostral pole, with no immunolabeled cells pre-
sent. The nucleus quickly fills with a dense plexus of fibers,
terminals, and numerous immunoreactive neurons by
midcaudal levels. Heavy cell and fiber immunolabeling
predominates within the medial division, whereas the
lateral division contains primarily fibers and has very few
immunolabeled neurons (Fig. 12D). The medial amygda-
loid nucleus presents a variable staining pattern from its
rostral to caudal poles. In its rostral pole, very lightly
labeled fibers are seen in the anteroventral division. At the
emergence of the anterodorsal division, fiber staining
increase significantly, and lightly stained immunolabeled
cells are observed. Throughout the caudal one-third of this
nucleus, the posterodorsal division is filled with darkly
stained fibers, terminals, and OFQ-containing neurons
(Fig. 12B). The posteroventral division contains scattered,
lightly labeled cells and fibers in its core and is surrounded
by a dense plexus of fibers and terminals (Figs. 1C, 12B).
Lateral to this region, scattered, moderately immunola-
beled cells and fibers are observed in the intercalated
nuclei. The intraamygdaloid division of the bed nucleus of
the stria terminalis contains light fiber and terminal
labeling with scattered, lightly labeled cells (Fig. 12D).
The bed nucleus of the lateral olfactory tract contains
scattered, lightly stained neurons with moderately stained
fibers. Immunolabeling in the remaining amygdaloid nu-
clei is sparse and includes lightly labeled, scattered cells
and fibers in the basomedial and basolateral nuclei (Fig.
12D); light neurons and moderate fibers scattered through-
out the posteromedial cortical nucleus; and light fibers in
the anteromedial cortical nucleus. The amygdalohippocam-




In situ hybridization. At the level of the septal
nuclei, the septohippocampal nucleus contains moderate
mRNA expression. Dorsal to the corpus callosum, a cluster
of intense mRNA-expressing neurons resides in the indu-
sium griseum, persisting throughout its rostral-to-caudal
extent. Ventral to this structure, the subfornical organ
contains numerous mRNA-expressing neurons. The fornix
is devoid of mRNA expression. More caudally, the dentate
gyrus contains moderate numbers of prepro-OFQ-contain-
ing neurons, primarily within the granule cell layer. There
are occasional scattered neurons within the molecular
layer rostrally and within the polymorph layer caudally
(Fig. 13A). The dentate hilus contains no mRNA expres-
sion.
Fig. 11. A,B: Darkfield autoradiogram (A) and brightfield photomi-
crograph (B) of the supramammillary nucleus of the hypothalamus
illustrating distribution of the prepro-OFQ precursor mRNA and OFQ
peptide in this nucleus. C,D: Darkfield photomicrographs demonstrat-
ing absence of OFQ mRNA expression in the anterior and intermedi-
ate lobes of the pituitary (C) and pineal glands (D). For abbreviations,
see list. Scale bar 5 200 µm in A,D, 100 µm in B, 400 µm in C.
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In Ammon’s horn, the CA1 field contains strong mRNA
expression. Rostrally, it is primarily within the stratum
pyramidal, with occasional mRNA-expressing neurons in
the stratum radiatum (Fig. 13A). There is no mRNA
expression detected in the stratum oriens. At more caudal
levels, particularly in the ventral CA1 region, light mRNA
expression is also observed in the stratum oriens. At
rostral levels, little mRNA expression is detected in area
CA2. This is in sharp contrast to the heavy mRNA levels
observed in the adjacent CA1 and CA3 regions. In the
caudal hippocampus, CA2 mRNA expression increases
slightly in the pyramidal layer. An occasional mRNA-
expressing neuron is observed in the stratum radiatum of
area CA2, but no mRNA expression is observed in the
stratum oriens. Rostrally in the CA3 field of Ammon’s
horn, there are numerous OFQ-containing neurons in the
stratum lucidum extending into the hippocampal field
from the stratum pyramidal, where scattered, mRNA-
containing neurons are observed. This persists into the
caudal regions, where mRNA levels in the ventral CA3
field decrease in the stratum lucidum and increase in the
stratum pyramidal. Messenger RNA expression in the
stratum radiatum of area CA3 is very light. In the dorsal
subiculum, moderate mRNA expression persists through-
out, with most OFQ-containing neurons confined to the
pyramidal layer. In the ventral subiculum, mRNA expres-
sion is weak rostrally but increases in its more caudal
aspect. Neurons expressing OFQ mRNA are numerous and
most dense in the pyramidal layer. Scattered neurons also
are seen in the stratum radiatum and the stratum molecu-
lar. In the caudal forebrain, mRNA expression is light in
the presubiculum and slightly heavier in the parasubicu-
lum at all levels.
Immunohistochemistry. In the rostral forebrain, the
indusium griseum is densely packed with dark, immunore-
active fibers and cells. Ventral to this structure, staining
extends into the septohippocampal nucleus and the tenia
tecta (Fig. 6B). The subfornical organ contains moderate
fiber labeling and scattered, lightly labeled cells. The
fornix is devoid of immunolabeling.
In the dorsal dentate gyrus, moderate, darkly stained
cells are scattered along the granule cell layer, with
occasional lightly stained cells in the polymorph and
molecular layers (Fig. 13B). These moderately sized cells
likely represent interneurons and are localized primarily
along the inner border of the polymorph layer, with fibers
extending perpendicularly into the molecular layer. In the
ventral dentate, neuronal immunolabeling becomes slightly
more pronounced within the polymorph layer. The alveus
contains no immunolabeling at all levels of the hippocam-
pal formation. In the CA3 field of Ammon’s horn, moder-
ately sized, darkly immunolabeled cells are observed in
the stratum pyramidal near the dentate hilus. In this
region, moderately labeled fibers are seen extending into
the stratum lucidum and the stratum oriens (Fig. 13C).
Approaching the transition to CA2, immunolabeled pyra-
Fig. 12. Photomicrographs of mRNA expression and immunolabel-
ing in the amygdala. A: Prepro-OFQ mRNA expression in the caudal
medial nucleus. B: Brightfield photomicrograph of OFQ immunoreac-
tivity in the posterodorsal and posteroventral parts of the medial
nucleus (colchicine treated). C: OFQ mRNA expression in the central
nucleus. D: Immunolabeling in the medial and lateral divisions of the
central nucleus, basolateral nucleus, and intraamygdaloid bed nucleus
of the stria terminalis (colchicine treated). For abbreviations, see list.
Scale bar 5 180 µm in A, 200 µm in B,C, 100 µm in D.
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midal cells decrease in number, and numerous, darkly
labeled neurons are observed in the stratum lucidum. In
caudal CA3, moderate numbers of intensely stained neu-
rons reside in the stratum pyramidal, and slightly fewer
are seen in the stratum lucidum (Fig. 13C). Neuronal
immunolabeling in the stratum radiatum is very sparse
throughout the CA3 region. Very little immunolabeling is
observed in area CA2 throughout its entire extent. Sparse,
lightly labeled cells are seen in the stratum pyramidal.
Moderately immunolabeled neurons are scattered scantly
in the stratum radiatum adjacent to the dentate molecular
layer. There is no fiber labeling noted in CA2. In area CA1,
numerous darkly labeled neurons reside in the stratum
pyramidal, with moderate fibers radiating into both the
stratum oriens and the stratum radiatum near the dentate
molecular layer (Fig. 3A). In ventral CA1, there is a
dramatic decrease in stratum pyramidal neurons, with a
moderate increase in orphanin-containing neurons in the
stratum radiatum. Negligible fiber labeling is observed in
caudal CA1. As CA1 transitions into the dorsal subiculum,
there is a slight decrease in cell size, but the intensity of
neuronal labeling remains strong (Fig. 13D). Perikarya
are scattered throughout the dorsal region, with occa-
sional scattered fibers also observed. Compared with its
dorsal part, OFQ immunolabeling is decreased in the
ventral subiculum. The presubiculum and parasubiculum
contain scattered, lightly labeled cells with no immunola-
beled fibers. The lamina dissecans of the entorhinal cortex
is devoid of labeling.
Thalamus
In situ hybridization. In the caudal basal telencepha-
lon, moderate mRNA expression in the anteroventral
thalamic nucleus is observed adjacent to the posterior bed
nucleus of the stria terminalis. At this level, strong mRNA
expression fills the paratenial nucleus and extends into
the anterior paraventricular and reuniens nuclei, where
more moderate mRNA levels are observed. Messenger
RNA expression in the paraventricular nucleus extends
caudal to the posterior division, remaining moderate into
its caudal pole. No OFQ mRNA expression is observed in
the anterodorsal, anteromedial, interanterodorsal, paracen-
tral, or rhomboid thalamic nuclei. In the caudal one-third
of the medial thalamic group, mRNA levels in the medial
habenula are very light. The lateral habenula contains
slightly more mRNA expression than the medial habenula,
which is most pronounced in its caudal one-third. Scat-
tered neurons containing OFQ mRNA are observed in the
laterodorsal and mediodorsal thalamic nuclei. No mRNA
expression is observed in the centromedial, centrolateral,
or lateroposterior thalamic nuclei, in the mammillotha-
lamic tract, or in the stria medullaris.
Lateral to the midline thalamic group, the reticular
nucleus contains the heaviest mRNA expression in the
entire thalamic region (Fig. 14A). Messenger RNA-
expressing neurons are moderate rostrally but become
very intense in the middle one-third, filling the nucleus
throughout its rostral-to-caudal extent. Ventromedially,
Fig. 13. Photomicrographs of orphanin mRNA expression in un-
treated animals and protein expression in colchicine-treated animals
in the hippocampal formation. A: Prepro-OFQ mRNA expression in
the dentate gyrus and CA1 region of Ammon’s horn. B: Brightfield
photomicrograph of OFQ immunoreactivity in the dentate gyrus.
C: Higher power, detailed image of immunolabeling in CA3 area of
Ammon’s horn. D: Immunolabeling in the dorsal subiculum. For
abbreviations, see list. Scale bar 5 400 µm in A, 200 µm in B–D.
526 C.R. NEAL, JR. ET AL.
intense mRNA expression from the reticular nucleus ex-
tends into the zona incerta, with high intensity in the
ventral zona incerta and lower intensity in its dorsal
division. Occasional OFQ-containing neurons are observed
in the subincertal nucleus and farther caudal in the
subgeniculate nucleus, just rostral to the peripeduncular
nucleus in the midbrain. No mRNA expression is detected
in the fields of Forel or in the ventrolateral, ventromedial,
ventral posterolateral, and ventral posteromedial tha-
lamic nuclei.
In the midbrain thalamus, mRNA expression is confined
to scattered neurons in the rostral interstitial nucleus of
the medial longitudinal fasciculus. This mRNA expression
extends laterally into the subparafascicular nucleus of the
thalamus, where mRNA levels are moderate. This mRNA
expression remains strong throughout the parvocellular
part of this nucleus, with scattered mRNA-expressing
neurons in the adjacent prerubral fields. Laterally, there is
no mRNA expression detected in the medial geniculate
nucleus, and only occasional mRNA-expressing neurons
are seen in the lateral geniculate. Adjacent to these
structures, the suprageniculate thalamic nucleus contains
a cluster of moderate mRNA-expressing cells, and the
posterior thalamic group contains numerous, scattered,
mRNA-containing neurons, particularly within the poste-
rior limitans thalamic nucleus, where mRNA levels are
moderate. At the emergence of the mesencephalon, the
precommissural nucleus contains moderate mRNA expres-
sion.
Immunohistochemistry. The anterior paraventricu-
lar nucleus contains a moderate accumulation of terminals
with dispersed fibers and occasional lightly labeled neu-
rons. The adjacent paratenial nucleus is filled with fine
terminals and fibers and with no immunolabeled neurons.
This fine fiber and terminal field spreads dorsolaterally
across the paracentral nucleus and into the adjacent
anterodorsal nucleus. Very dense terminal labeling is seen
at this level in the interanterodorsal thalamic nucleus. It
persists throughout the nucleus and does not extend into
adjacent regions. This immunolabeling pattern is observed
in colchicine-treated and untreated animals. The antero-
ventral nucleus contains occasional lightly labeled fibers
with no terminals. Lightly labeled fibers are scattered in
the reuniens and rhomboid nuclei at this level, but no
immunolabeled perikarya are identified. The stria medul-
laris is devoid of immunolabeling. The reticular nucleus
contains numerous, intensely stained neurons in its dorsal
aspect, with decreased numbers of immunoreactive neu-
rons ventrally (Fig. 14B,C). There are lightly labeled,
sparse fibers interspersed among the cells in the dorsal
region. This pattern of labeling persists to its caudal
extent, with ventromedial extension of immunolabeled
neurons into the zona incerta. In untreated animals, the
zona incerta also contains moderate amounts of immunola-
Fig. 14. Photomicrographs of mRNA expression and immunolabel-
ing in the thalamus. A: Low-power, darkfield autoradiogram of
prepro-OFQ mRNA expression in the reticular nucleus of the thala-
mus. B: Low-power image of immunolabeling at a similar level of the
reticular nucleus (colchicine treated). C: High-power, detailed view of
immunostaining in the reticular nucleus. D: Brightfield photomicro-
graph from the brainstem thalamus illustrating fiber and cell staining
in the subparafascicular nucleus. For abbreviations, see list. Scale
bar 5 360 µm in A, 400 µm in B, 50 µm in C, 100 µm in D.
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beled fibers and puncta. No immunolabeling is observed in
the adjacent prerubral field and the nuclear fields of Forel.
Dorsal to these structures, there is prominent cell, fiber,
and terminal labeling in the subparafascicular thalamic
nucleus (Fig. 14D).
In the caudal thalamus, a dense, immunoreactive fiber
bundle courses through the medial habenula. Medial to
this fiber bundle, scattered, darkly stained neurons are
observed. Staining in the lateral habenula is confined to
scattered, lightly labeled terminals. This light terminal
staining extends medioventrally into the posterior paraven-
tricular nucleus, where lightly labeled terminals, fibers,
and scattered immunolabeled neurons are observed to in
its caudal pole. Here, a dramatic increase in terminal
labeling occurs in the transition into the precommissural
nucleus, where moderate immunolabeled fibers and cells
are observed. The remainder of the thalamus is relatively
devoid of immunolabeling. The anteromedial, central me-
dial, laterodorsal, mediodorsal, and centrolateral nuclei
and the ventral nuclear group contain no immunolabeling.
Caudally, there is light staining noted in the posterior
thalamic nuclear group, the lateral posterior nucleus, the
subgeniculate nucleus, and the lateral and medial genicu-
late bodies. Adjacent to these nuclei, the suprageniculate
thalamic nucleus and posterior limitans thalamic nucleus
contain lightly stained neurons, with no fiber or terminal
labeling noted.
Mesencephalon
In situ hybridization. Messenger RNA expression in
brainstem thalamic and basal ganglia structures is de-
scribed above. In the rostral ventral midbrain, moderate
mRNA expression is observed initially within the rostrolat-
eral subdivision of the interpeduncular nucleus. Message
expression intensifies into the lateral and dorsal divisions
and remains strong (Fig. 15A). The mammillary peduncle,
fasciculus retroflexus, rubrospinal tract, and medial and
lateral lemniscus are devoid of mRNA expression at this
level. The rostral ventral tegmental area contains scat-
tered neurons expressing OFQ mRNA. These levels in-
crease substantially in the ventral tegmental area proper,
where moderate-to-heavy mRNA expression is localized
ventromedially and extends into its dorsolateral part. The
paranigral nucleus contains intense expression through-
out its extent (Fig. 15C). No expression is observed in the
prerubral field or parabrachial pigmented nucleus.
In the rostral dorsal midbrain, the olivary pretectal
nucleus contains no mRNA expression, with moderate
expression in the ventral anterior pretectal region. Moder-
ate mRNA expression is seen also in the nucleus of the
optic tract and in the posterior pretectal nucleus, and a
cluster of intense mRNA expression is observed in the
nucleus of the posterior commissure, with lighter mRNA
expression into its magnocellular part. No mRNA-express-
Fig. 15. Photomicrographs of mRNA expression and immunolabel-
ing in the ventral rostral mesencephalon. A: Prepro-OFQ mRNA
expression in the interpeduncular nucleus. B: Brightfield photomicro-
graph of OFQ protein expression in the interpeduncular nucleus
demonstrates immunolabeled neurons that are concentrated mostly in
its rostral division (colchicine treated). C: High-powered view of
mRNA-expressing neurons in the ventral tegmental area at the level
depicted in A (arrows). D: Scattered, immunolabeled neurons in the
ventral tegmental area (colchicine treated). For abbreviations, see list.
Scale bar 5 200 µm in A, 100 µm in B–D.
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ing neurons are observed in the posterior commissure or in
the commissure of the superior colliculus. In the superior
colliculus, mRNA expression is sparse in the superficial
gray and is distributed more moderately in the optic and
intermediate gray layers. Other than occasional scattered
neurons within the deep gray layer, no other layer of the
superior colliculus contains OFQ mRNA expression. In the
inferior colliculus, the external cortex contains numerous
mRNA-expressing neurons in layers II and III. Occasional
scattered neurons are observed in layers II and III of the
dorsal cortex of the inferior colliculus, with negligible
mRNAexpression observed in the central collicular nucleus,
the intercollicular nucleus, and the commissure of the
inferior colliculus.
Laterally in the rostral midbrain, heavy mRNA expres-
sion in the substantia nigra, pars compacta, persists into
the pars lateralis and intensifies farther away at the
medial edge of the peripeduncular nucleus, which contains
intense expression throughout its extent (Fig. 2E). The
retrorubral field contains moderate numbers of mRNA-
containing neurons. The brachium of the inferior colliculus
and its nucleus contain no mRNA expression, whereas
lightly scattered neurons are present within the sub-
brachial nucleus. Negligible mRNA expression is observed
in the cuneiform nucleus; in the dorsal, intermediate, and
ventral nuclei of the lateral lemniscus; in the mesence-
phalic trigeminal nucleus; in the paralemniscal nucleus;
and in the retrorubral nucleus.
In the midline of the rostral midbrain, the nucleus of
Darkschewitsch is filled completely with the most intense
mRNA expression in the mesencephalon. OFQ-expressing
neurons fill this nucleus throughout its rostral-to-caudal
extent and extend ventrolaterally into the interstitial
nucleus of the medial longitudinal fasciculus, where mRNA
expression is quite strong (Fig. 16C). Dorsal to the nucleus
of Darkschewitsch, the central gray also contains very
strong expression, which is more prominent in the ventral
part of the nucleus, spreading to its lateral borders (Fig.
16A). There is a dramatic drop in mRNA intensity in the
dorsal central gray, which contains only moderate mRNA
levels. Scattered mRNA-expressing neurons are present in
its pontine division. Ventral to the central gray, the
Edinger-Westphal and medial accessory oculomotor nuclei
are conspicuously devoid of mRNA expression (Fig. 16C).
In contrast, the supraoculomotor central gray is moder-
ately labeled with OFQ-containing neurons. Farther cau-
dally, the raphe nuclear complex contains prominent mRNA
expression. The rostral linear raphe nucleus contains
moderate mRNA expression. Just posterior to this region,
in the caudal linear raphe nucleus, light to moderate
mRNA levels are observed. The dorsal raphe emerges with
moderate mRNA expression, which persists throughout its
rostral-to-caudal extent. Numerous mRNA-containing neu-
rons are observed also throughout the caudal linear raphe
ventrally, with extension caudally into the median raphe
(Fig. 18A). The paramedian raphe contains little mRNA
Fig. 16. Messenger RNA expression and immunolabeling in the
periaqueductal region of the mesencephalon. A: mRNA-expressing
neurons in the ventral central gray. B: Brightfield photomicrograph of
intensely immunolabeled neurons in the ventral division of the central
gray. C: Robust orphanin mRNA expression in the nucleus of Darks-
chewitsch and the interstitial nucleus of the medial longitudinal
fasciculus. D: Intense orphanin immunolabeling in the interstitial
nucleus of the medial longitudinal fasciculus and the nucleus of
Darkschewitsch (colchicine treated). For abbreviations, see list. Scale
bar 5 200 µm in A,C,D, 100 µm in B.
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expression (Fig. 18A), and the paratrochlear nucleus con-
tains no mRNA expression.
In the remainder of the midbrain, scattered, mRNA-
expressing neurons are observed within the deep mesence-
phalic nucleus and in the magnocellular and parvocellular
parts of the red nucleus. The central trigeminal tract,
dorsal longitudinal fasciculus, rhabdoid nucleus, superior
cerebellar peduncle, microcellular, subpeduncular and ven-
trolateral tegmental nuclei, sensory root of the trigeminal
nerve, reticulotegmental nucleus, and rostral pontine nu-
clei are devoid of mRNA expression. Moderate mRNA
expression is observed in the pontine reticular nucleus, in
its oral and caudal parts, extending laterally into the
pedunculopontine tegmental nucleus, where mRNA levels
increase. Moderate mRNA expression is observed also in
the dorsal, laterodorsal, and ventral tegmental nuclei. The
nucleus of the trapezoid body contains heavy mRNA
expression at the emergence of the ventral metencephalon.
Immunohistochemistry. Immunohistochemical stain-
ing in brainstem thalamic and basal ganglia structures is
described above. Rostrally, the interpeduncular nucleus
contains strong immunolabeling. There are numerous
immunolabeled neurons in the rostral division (Fig. 15B),
and only lightly labeled, scattered neurons are found in the
caudal and lateral divisions. The dorsal division contains
darkly labeled neurons with moderate fibers and termi-
nals that extend into the ventral tegmental area. No
immunolabeling is observed in the prerubral field, and
lightly scattered OFQ-containing fibers are seen in the
parvocellular part of the red nucleus. Fibers extend to the
magnocellular part, where lightly stained, immunolabeled
neurons are seen. The retrorubral field contains light cell
immunolabeling, with scattered fibers in its ventrolateral
aspect. This pattern extends caudally and ventrolaterally
into the pedunculopontine tegmental nucleus, where darkly
stained neurons are present. The rostral ventral tegmen-
tal area contains numerous moderately stained neurons
and lightly stained fibers scattered throughout. This stain-
ing pattern intensifies caudally into the ventral tegmental
area proper (Fig. 15D), where scattered, darkly labeled
neurons and fibers extend from the dorsolateral interpe-
duncular nucleus into this region. Scattered, darkly stained
neurons spread from the lateral part of the ventral tegmen-
tal area into the paranigral nucleus, where moderately
stained neurons and scattered fibers are observed. Cau-
dally, immunolabeled neurons in the substantia nigra,
pars lateralis, extend to the peripeduncular nucleus, where
numerous, intensely stained neurons fill the region. Mod-
erate fiber staining also fills this nucleus and is observed
best in untreated animals. Moderate fibers are observed
also in the medial lemniscus and dorsally in the region of
Fig. 17. Photomicrographs of orphanin mRNA and protein expres-
sion in the dorsal metencephalon. A: mRNA-expressing neurons are
numerous in the locus coeruleus, whereas the adjacent mesencephalic
trigeminal nucleus is devoid of mRNA expression. B: Brightfield
photomicrograph of OFQ immunoreactivity in the locus coeruleus.
Again, note the lack of immunolabeling in the adjacent mesencephalic
trigeminal nucleus in this colchicine-treated animal. C: Lightly immu-
nolabeled neurons and fibers in the dorsal raphe with intense immuno-
labeling in the dorsal tegmental and laterodorsal tegmental nuclei
(colchicine treated). D: Moderate fiber and terminal labeling in the
lateral parabrachial nucleus (colchicine treated). Scattered, lightly
immunolabeled neurons also are evident. For abbreviations, see list.
Scale bar 5 100 µm.
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the deep mesencephalic nuclei. The cerebral and mammil-
lary peduncles are without immunostaining.
In the dorsal region of the rostral midbrain, several
moderately immunostained neurons are observed in the
nucleus of the posterior commissure, the posterior pretec-
tal nucleus, the olivary pretectal nucleus, and the nucleus
of the optic tract. Lightly labeled, scattered neurons are
observed in the magnocellular nucleus of the posterior
commissure. There is moderate to heavy neuronal labeling
with light fiber labeling in the dorsal and ventral divisions
of the anterior pretectal nucleus. Lightly labeled, OFQ-
containing fibers also are seen in the nucleus of the optic
tract. The posterior commissure, the commissure of the
superior colliculus, and the central tegmental tract are
devoid of immunolabeling. In the superior colliculus, the
zonal layer contains occasional lightly labeled fibers but no
immunolabeled neurons. There are moderate numbers of
lightly labeled neurons in the superficial gray layer that
increase in number and intensity of staining in the optic
nerve and intermediate gray layers, where labeled neu-
rons are moderately stained. Although fibers are present
in these layers, they remain very sparse, even in untreated
animals. No immunolabeling is observed in the intermedi-
ate white, deep white, or deep gray layers of the superior
colliculus or in the intercollicular nucleus. In the inferior
brachium, scattered, moderately stained cells are observed
primarily in layers II and III of the external cortex. There
are very few fibers, and no terminal labeling in this region.
This pattern persists to the caudal extent of the external
cortex of the inferior colliculus. Occasional lightly labeled
fibers and cells are observed in the dorsal cortex, and the
central nucleus contains only an occasional scattered,
lightly stained neuron. There is no immunolabeling in the
brachium of the inferior colliculus or in the commissure of
the inferior colliculus. Within the nucleus of the brachium
of the inferior colliculus, moderately stained fiber pro-
cesses are observed.
At the midline, numerous, intensely stained neurons,
fibers, and terminals fill the ventral and lateral aspects of
the central gray (Fig. 16B). The heaviest fiber and termi-
nal immunolabeling is observed adjacent to the aqueduct,
with only scattered, lightly labeled cells and fibers in the
dorsal central gray. In caudal central gray regions, immu-
nolabeling of neurons increases in its dorsal part. Ventro-
lateral to the central gray rostrally, numerous, intensely
immunolabeled cells with moderate fibers and terminals
fill the nucleus of Darkschewitsch (Fig. 16D). This intense
immunolabeling persists to the caudal extent of this
nucleus. Strongly immunolabeled neurons and fibers ex-
tend ventrolaterally to the interstitial nucleus of the
medial longitudinal fasciculus (Fig. 16D). Lightly scat-
tered cells are observed also in the deep mesencephalic
nuclei of the midbrain. No immunolabeling is observed in
the Edinger-Westphal nucleus, the medial accessory oculo-
motor nucleus, the supraoculomotor central gray, the
dorsal longitudinal fasciculus, or the superior cerebellar
peduncle. Ventral to the central gray, several lightly
immunolabeled neurons with scattered fibers reside in the
Fig. 18. Photomicrographs of mRNA expression and immunolabel-
ing in brainstem raphe regions. A: mRNA-expressing neurons are
scattered in the median and paramedian raphe nuclei. B: Immunola-
beled neurons and fibers in the median and paramedian raphe nuclei.
C: mRNA expression in the raphe magnus and raphe pallidus nucleus.
D: Darkly immunolabeled neurons in the raphe magnus and raphe
pallidum. For abbreviations, see list. Scale bar 5 100 µm in A,B, 200
µm in C,D.
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dorsal raphe (Fig. 17C). This labeling pattern extends
along the midline into the median raphe. The adjacent
paramedian raphe also contains scattered, darkly stained
cells (Fig. 18B). Scattered neurons with moderate staining
are observed in the rostral linear raphe. This pattern
continues into the caudal midbrain, with scattered dark
neurons and lightly labeled fibers in the caudal linear
raphe. Scattered fibers and cells also are observed in the
anterior (Fig. 18B) and ventral tegmental nuclei. The
laterodorsal and dorsal tegmental nuclei contain numer-
ous, darkly labeled neurons and fibers (Fig. 17C). The
reticulotegmental, subpeduncular, and ventrolateral teg-
mental nuclei are devoid of labeling.
In the caudal mesencephalon, the pontine reticular
nucleus contains scattered, moderately stained neurons
and lightly labeled fibers in its oral part. This labeling
extends laterally into the paralemniscal nucleus. No immu-
nolabeling is observed in the lateral lemniscus or in the
ventral, dorsal, or lateral nuclei associated with it. The
cuneiform nucleus, mesencephalic trigeminal nucleus,
paratrochlear nucleus, parabigeminal nucleus, longitudi-
nal fasciculus, rubrospinal tract, and sensory root of the
trigeminal nerve are devoid of immunolabeling. Ventrolat-
erally at this level, scattered, lightly immunolabeled fibers
are present in the pontine nuclei, and caudally, moderate
numbers of modestly stained neurons lie in the nucleus of
the trapezoid body and the in the rostral preolivary region,
entering the rostral metencephalon.
Metencephalon
In situ hybridization. In the dorsal rostral pons, the
locus coeruleus contains moderate mRNA expression (Fig.
17A) with light to moderate levels in the pontine central
gray and adjacent dorsal raphe. Moderate to intense
mRNA expression is observed in the dorsomedial tegmen-
tal area and the laterodorsal tegmental nucleus, with
increased mRNA expression caudally in the posterodorsal
tegmental nucleus. The lateral parabrachial nucleus con-
tains numerous, scattered, OFQ-containing neurons,
whereas the medial parabrachial nucleus is devoid of
mRNA expression. Negligible expression is observed in the
subcoeruleus nucleus, principal sensory trigeminal nucleus,
Kolliker-Fuse nucleus, trigeminal motor nucleus, anterior
ventral cochlear nucleus, medial longitudinal fasciculus,
mesencephalic trigeminal nucleus (Fig. 17A), and superior
cerebellar peduncle.
In the ventral rostral pons, the nucleus of the trapezoid
body contains intense mRNA expression, with light-to-
moderate expression in the adjacent superior paraolivary
nucleus (Fig. 19A). Moderate-to-strong mRNA expression
is observed in the medioventral periolivary nucleus, with
scattered neurons observed in the dorsal, lateroventral,
and superior periolivary nuclei and in the lateral superior
olive (Fig. 19B). No mRNA expression is observed in the
caudal periolivary nucleus or medial superior olive. Scat-
tered neurons with intense mRNA levels reside in the
region of the A5 cell group (Fig. 19A), whereas no OFQ
mRNA is detected in the A7, C1, C2, or C3 cell groups. The
pyramidal tract and the root of the abducens nerve contain
no mRNA expression.
In the caudal pons, no mRNA expression is seen in the
sixth, seventh, or eighth nerves or in the associated
abducens and facial nuclei. Laterally, the paratrigeminal
nucleus contains a cluster of moderate mRNA-expressing
neurons. In the vestibular complex, light to moderate
mRNA expression is scattered throughout the superior
and medial vestibular nuclei, primarily in their dorsal
parts. Messenger RNA levels are slightly higher in the
lateral vestibular nucleus, mostly in its lateral part.
Moderate mRNA expression is observed in the caudal half
of the medioventral vestibular nucleus, and scattered
mRNA-expressing cells are observed in the spinal vestibu-
lar nucleus and dorsal cochlear nucleus. The ventral
Fig. 19. Photomicrographs of mRNA expression and immunolabel-
ing in the in the caudal metencephalon. A: mRNA expression in the
superior paraolivary nucleus. Note scattered mRNA-expressing neu-
rons within the region of the A5 cell group. B: Higher power view of
scattered mRNA-expressing neurons in the medioventral and latero-
ventral periolivary nuclei. C: Brightfield photomicrograph of moder-
ately immunolabeled neurons in the ventral part of the medial
vestibular nucleus (colchicine treated). For abbreviations, see list.
Scale bar 5 200 µm in A,B, 100 µm in C.
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posterior cochlear nucleus and inferior cerebellar peduncle
are devoid of mRNA expression. In the dorsal caudal pons,
the abducens nucleus has no mRNA expression, but the
adjacent supragenual nucleus contains moderate mRNA
expression. This persists caudally into the prepositus
hypoglossus, where intense mRNA expression is observed
throughout its extent (Fig. 20A). In the reticular forma-
tion, scattered neurons expressing OFQ mRNA are ob-
served in the parvocellular, intermediate, and dorsal para-
gigantocellular reticular nuclei. Large neurons with
moderate intensity are observed in the gigantocellular
nucleus and its alpha subdivision. Only sparse mRNA
expression is observed in the lateral paragigantocellular
nucleus in the pons, intensifying in the medulla (Fig. 20E).
In the pontine raphe complex, modest mRNA expression
in the dorsal raphe persists caudally in its dorsal exten-
sion, whereas high mRNA expression is observed in the
pontine raphe nucleus. Moderate mRNA expression is
observed in the oral pontine reticular nucleus and becomes
more sparse into the caudal pontine reticular nucleus. In
Fig. 20. Photomicrographs of OFQ mRNA and protein expression
in the mylencephalon. A: Intense mRNA expression in the prepositus
hypoglossus. Dashed lines outline the boundary of the 4th ventricle.
B: Brightfield photomicrograph of darkly immunolabeled neurons in
the prepositus hypoglossus. C: mRNA-expressing cells in the medial
and lateral divisions of the midcaudal solitary nucleus. D: Immunola-
beling in the medial and lateral divisions of the solitary nucleus
(colchicine treated). E: mRNA-expressing neurons in the medullary
lateral paragigantocellular reticular nucleus. F: Immunolabeling in
the inferior olivary nucleus demonstrating scattered cells, fibers, and
terminals in the medial, dorsal, and principal divisions (colchicine
treated). For abbreviations, see list. Scale bar 5 200 µm in A, 100 µm
in B–F.
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the caudal pons, intense mRNA expression is observed in
the raphe magnus and raphe pallidus (Fig. 18C), but is
much decreased in the ventral pontine reticular nucleus.
The spinal trigeminal nuclear complex has a varied mRNA
expression pattern, from rostral to caudal. Rostrally, the
principal sensory trigeminal nucleus is devoid of mRNA
expression; however, in the caudal pons, the oral and
interpolar parts of the spinal trigeminal nucleus contain
scattered, mRNA-containing neurons. Messenger RNA
expression does not increase until the emergence of the
caudal spinal trigeminal nucleus in the medulla (Fig. 21A).
Immunohistochemistry. Immunolabeling in the dor-
sal part of the rostral pons is generally sparse. The
mesencephalic trigeminal nucleus and subcoeruleus con-
tain no immunolabeling. The locus coeruleus contains
modest numbers of darkly stained neurons and lightly
Fig. 21. Photomicrographs of mRNA expression and immunolabel-
ing in the caudal medulla and spinal cord. A: mRNA-expressing
neurons in the caudal spinal trigeminal nucleus with extension
medially into the dorsal medullary reticular nucleus and ventrally
into the retroambiguous nucleus. B: Brightfield photomicrograph of
immunolabeling within the caudal part of the spinal trigeminal
nucleus demonstrating heavily immunolabeled fibers and terminals
with scattered, intensely labeled neurons. Note that immunolabeling
is confined primarily to the lateral part of the nucleus (colchicine
treated). C: mRNA expression in the dorsal horn of the cervical spinal
cord demonstrating heavy expression within laminae II and III.
D: Immunolabeling in the dorsal horn demonstrating terminals and
scattered neurons within laminae II and III (colchicine treated).
E: mRNA-expressing neurons in lamina X and in the intermediome-
dial cell column of the thoracic spinal cord. F: Immunolabeled fibers
and cells within the lateral spinal nucleus (colchicine treated). For
abbreviations, see list. Scale bar 5 200 µm in A,C, 100 µm in B,E,F,
50 µm in D.
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labeled terminals (Fig. 17B). Scattered, lightly labeled
neurons are present in the pontine central gray and in the
laterodorsal and posterodorsal tegmental nuclei. The dor-
somedial tegmental nucleus contains a cluster of moder-
ately immunolabeled neurons with scattered fibers. In the
lateral region of the dorsal metencephalon, moderate cell
and light fiber immunostaining is present in the lateral
parabrachial nucleus (Fig. 17D). The superior cerebellar
peduncle, medial parabrachial nucleus, A7 noradrenaline
cell group, and Kolliker-Fuse nucleus are devoid of immu-
nolabeling.
In the ventral rostral pons near the midline, the nucleus
of the trapezoid body is filled with darkly immunolabeled
neurons and few lightly labeled fibers. The lateral rostral
periolivary region contains an occasional darkly labeled
neuron but is filled mostly with moderately immunola-
beled fibers and terminals, which are seen well in un-
treated animals. Moderately immunolabeled cells and
fibers are observed in the superior periolivary nucleus,
lateroventral periolivary nucleus, medioventral perioli-
vary nucleus, and lateral superior olive. The medial supe-
rior olive is devoid of immunolabeling. Cell immunolabel-
ing is present in the lateral and dorsal superior olive but is
significantly less than that observed in the periolivary
nuclei. Occasional lightly labeled fibers and no cells reside
in the caudal periolivary nucleus. Scattered, lightly immu-
nolabeled neurons are observed in the region of the A5
noradrenaline cell group. Immunolabeling was not ob-
served in the C1, C2, or C3 adrenaline cell groups.
In the caudal pons, lightly immunolabeled cells and
fibers are observed primarily extending through the me-
dial, lateral, and superior vestibular nuclei. Fiber staining
remains light throughout, but cells become more numer-
ous and darkly stained caudally in the medial nucleus and
laterodorsal part of the lateral vestibular nucleus. In the
midcaudal region of the superior vestibular nucleus, a
cluster of intense immunoreactivity is observed just adja-
cent to the inferior cerebellar peduncle. This extends as
light immunolabeling into the dorsal cochlear nucleus. At
caudal levels, more immunolabeled neurons are observed
in the superior, lateral, and ventral medial vestibular
nuclei (Fig. 19C), with decreased labeling in the medial
vestibular region. Scattered, darkly stained neurons are
observed in the spinal vestibular nucleus, continuing into
its caudal pole at the emergence of the solitary nucleus.
The anterior and posterior ventral cochlear nuclei are
devoid of labeling.
In the pontine raphe complex, the dorsal raphe contains
scattered, moderately immunolabeled cells and fibers,
which diminish significantly in the region of the dorsal and
laterodorsal tegmental nuclei (Fig. 17C). Neuronal immu-
nolabeling increases significantly ventral and caudal into
the pontine raphe nucleus and raphe magnus (Fig. 18D).
In the reticular formation, darkly immunolabeled peri-
karya are scattered throughout the gigantocellular, lateral
paragigantocellular, and lateral reticular nuclei. No immu-
noreactive fibers or terminals are observed in these re-
gions. The parvocellular reticular nucleus contains scat-
tered, lightly labeled fibers but is devoid of immunoreactive
cells. Few modestly labeled neurons are present in the
dorsal gigantocellular, caudal pontine, and lateral reticu-
lar nuclei. Cranial nerve nuclei and fibers are relatively
unlabeled in the pontine region. The oral trigeminal
nucleus does contain an occasional scattered fiber but has
no terminal or neuronal immunolabeling. The remainder
of the pontine cranial nerves and associated nuclei are
devoid of immunolabeling. Other regions with no detect-
able immunolabeling include the inferior cerebellar pe-
duncle, the medial longitudinal fasciculus, the pyramidal
tract, the sensory root of the trigeminal nerve, the motor
and principal sensory nuclei of the trigeminal nerve, and
the rostral and superior paraolivary nuclei.
Mylencephalon
In situ hybridization. In the cerebellar hemispheres,
preproorphanin mRNA expression is confined to scattered
neurons in the granular layer. No mRNA expression is
detected within the molecular or Purkinje cell layers of any
cerebellar lobule. Within the deep cerebellar nuclei, moder-
ate numbers of neurons expressing OFQ mRNA are ob-
served in the medial (fastigial) cerebellar nucleus, with
slightly less intensity in its dorsolateral protuberance. No
mRNA expression is detected in the lateral (dentate) or
interposed cerebellar nuclei.
Scattered OFQ-containing neurons are occasionally ob-
served in the external cuneate nucleus, with the cuneate
nucleus and nucleus gracilus both devoid of mRNA expres-
sion. There is no OFQ mRNA expression detected in the
ninth or twelfth cranial nerves, in the dorsal motor
nucleus of the tenth nerve, or in the hypoglossal nucleus.
The prepositus hypoglossus contains intense mRNAexpres-
sion, which is observed initially in the caudal pons, persist-
ing throughout its extent into the medulla (Fig. 20A). The
nucleus ambiguous is filled with intense mRNA expression
throughout its extent and at its caudal boundary. Messen-
ger RNA expression becomes slightly more intense into the
retroambiguous nucleus in the caudal medulla (Fig. 21A).
The rostral solitary nucleus emerges with moderate Mes-
senger RNA expression. This persists in the medial and
lateral subdivisions, with mRNA levels increasing cau-
dally. In the caudal extent of the solitary nucleus, mRNA
expression is very strong in its lateral and medial divisions
and is moderate in the commissural division (Fig. 20C).
Located within the solitary nuclear complex, the solitary
tract contains no mRNA expression.
In the ventral medulla, the inferior olivary complex
contains weak OFQ mRNA expression at its rostral bound-
ary. The medial and dorsomedial nuclei are devoid of
mRNA expression, with scattered mRNA-containing neu-
rons observed in its principal and dorsal nuclei as well as
in subnuclei A and B of the medial subdivision. In the
reticular formation, light-to-moderate mRNA expression
is seen in the gigantocellular, gigantocellular alpha, inter-
mediate, and parvocellular reticular nuclei, and more
intense expression is seen in the lateral paragigantocellu-
lar nucleus (Fig. 20E). The adjacent paramedian reticular
nucleus contains an occasional positive neuron but other-
wise is devoid of mRNA expression. Caudally, the lateral
reticular and paragigantocellular nuclei and the dorsal
and ventral medullary reticular fields contain scattered,
large neurons with strong mRNA expression. At the mid-
line, the caudal interstitial nucleus of the medial longitudi-
nal fasciculus contains intense mRNA expression, particu-
larly in its ventral aspect. Orphanin mRNA expression
persists in this nucleus to its caudal extent, extending to
the raphe obscurus. In the caudal part of the raphe
complex, the raphe magnus contains numerous intensely
labeled neurons, with a moderate number of OFQ-
containing neurons in the raphe pallidus nucleus to its
caudal extent (Fig. 18C).
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In the caudal mylencephalon, very strong mRNA expres-
sion is noted in the spinal trigeminal nucleus. Messenger
RNA expression is localized primarily in the lateral aspect
of this nucleus. Very strong mRNA expression extends
dorsally into the dorsomedial spinal trigeminal nucleus
and ventrally into the nucleus ambiguous and retroambigu-
ous nucleus caudally (Fig. 21A). Messenger RNA levels
remain moderate to strong throughout the dorsomedial
nucleus. Continuing into the transition into the cervical
spinal cord, mRNA intensity in the caudal spinal trigemi-
nal nucleus is the most intense in the mylencephalon.
Immunohistochemistry. No specific orphanin immu-
noreactivity was observed in the cerebellar hemispheres,
as stated above. A dense plexus of cells and fibers is
observed in the fastigial (medial) nucleus, with moderate
to heavy immunolabeling. This labeling drops off slightly
into its dorsolateral protuberance but is still quite strong
to its caudal extent. No immunolabeling is observed in the
dentate (lateral) or interposed cerebellar nuclei or any of
their corresponding parts.
Immunolabeling within the cranial nerve nuclei of the
medulla is relatively sparse. There is no immunolabeling
observed the in ninth, tenth, and twelfth cranial nerves or
in their associated nuclei. Throughout its extent, the
nucleus ambiguous contains a cluster of darkly immunola-
beled neurons with moderate fiber staining. This immuno-
labeling remains confined to this nucleus and persists to
the retroambiguous nucleus at the level of the pyramidal
decussation. The retroambiguous nucleus contains numer-
ous, densely immunolabeled, OFQ-containing neurons.
Very strong neuronal immunolabeling is also observed in
the prepositus hypoglossus, with dark immunoreactive
fibers visualized (Fig. 20B). At this level, the caudal
interstitial nucleus of the medial longitudinal fasciculus
contains moderate numbers of labeled neurons and fibers.
In the dorsal medulla, the nucleus of the solitary tract is
strongly immunolabeled. The inclusive solitary tract itself
is devoid of immunolabeling. A cluster of numerous, lightly
immunolabeled cells with dark fibers and terminals is seen
in the rostral solitary nucleus. At more caudal levels,
immunolabeling in the solitary nucleus diverges slightly,
with heavier terminal and fiber labeling in the medial and
lateral parts, and with heavier cell staining in the medial
and commissural parts (Fig. 20D). In this dorsal region,
darkly stained neurons are observed in the supragenual
nucleus medially, and the cuneate and external cuneate
nuclei and nucleus gracilus are devoid of immunolabeling.
Ventral to the solitary nucleus, darkly labeled neurons and
fibers are scattered throughout the reticular formation.
Scattered, moderately labeled neurons are observed in the
caudal gigantocellular reticular nucleus alpha and the
lateral paragigantocellular nucleus. The inferior olive
contains numerous darkly immunolabeled cells and scat-
tered fibers in its principal nucleus. There are also lightly
stained cells and scattered fibers within the anterior,
medial, and dorsal nuclei (Fig. 20F). The dorsomedial
division is without immunolabeling. The raphe nuclei in
this ventral medullary region contain scattered, moder-
ately labeled neurons into the caudal medulla. This OFQ
immunoreactivity is primarily in the raphe magnus and
pallidus (Fig. 18D), with scattered, lightly labeled fibers
and neurons in the midline raphe obscurus.
In the lateral medulla, the interpolar spinal trigeminal
nucleus contains sparse fiber labeling and no cell staining.
This persists until the emergence of the caudal spinal
trigeminal nucleus, which emerges with a heavily immuno-
labeled fiber and terminal field, interspersed with numer-
ous darkly labeled neurons (Fig. 21B). Similar to mRNA
expression, immunolabeling extends dorsally into the dor-
somedial spinal trigeminal nucleus, which contains moder-
ate cell and fiber staining, and ventrally into nucleus
ambiguous, where intense neuronal immunolabeling is
observed. The pattern of OFQ immunoreactivity in the
caudal spinal trigeminal nucleus persists past the caudal
medulla and into the cervical spinal cord as a continuum
with the heavy fiber and terminal fields in the dorsal horn.
Spinal cord
In situ hybridization. Proximally, intense mRNA
expression in the caudal spinal trigeminal nucleus transi-
tions into the rostral dorsal horn of the cervical cord,
where mRNA expression is intense in lamina II and is very
light in laminae III, V, and VI (Fig. 21C). Scattered
neurons are also seen in lamina VIII dorsally. Intense
mRNA expression is evident in lamina X adjacent to the
central canal. Extending ventrally from this region, large,
scattered neurons with strong mRNA expression are ob-
served in the ventral horn, in the ventral aspect of lamina
VII, and in what appear to be large ventral motor neurons
in lamina IX, which also are observed in immunohisto-
chemical staining (Fig. 2G). The lateral cervical nucleus
shows light mRNA expression. In the thoracic spinal cord,
lamina I is devoid of OFQ mRNA-containing neurons, but
lamina II has heavy expression. Other than occasional
neurons in laminae III and V, there is no other mRNA
expression observed in the dorsal horn. Messenger RNA
levels are moderate in lamina X of the thoracic cord, with
most neurons lying lateral in this region in the intermedio-
medial cell column, where moderate numbers of OFQ-
containing neurons are present (Fig. 21E). Again, there
are scattered, large, intensely labeled cells in the ventral
part of laminae IX of the ventral horn. The dorsal root
ganglia contains scattered cells expressing OFQ mRNA
that are very few in number and are confined centrally in
the ganglia. No mRNA expression is observed in the lateral
spinal nucleus, the intermediolateral cell column, the
dorsal corticospinal tract, the gracile fasciculus, the lateral
funiculus, or the ventral funiculus in the thoracic cord
region.
Immunohistochemistry. Proximally, intense immuno-
staining from the caudal spinal trigeminal nucleus per-
sists into laminae II and III of the dorsal horn (Figs. 3E,
21D). Lamina I contains scattered terminals and fibers,
which are observed best in untreated animals, but no cells.
The lateral cervical nucleus is filled with a dense plexus of
immunolabeled fibers with moderate cell staining
(Fig. 21F). Moderate puncta and fibers are seen in lamina
IV, and only lightly labeled, scattered terminals and
minimal fibers seen in laminae V and VI. Fiber and
terminal labeling increases in the dorsal part of lamina
VII, extending medially to form a moderate plexus of fibers
and terminals within lamina X. Several moderately la-
beled neurons also are found within this lamina. The
dorsal aspect of lamina VIII contains some lightly scat-
tered fibers and no neurons. Large immunolabeled neu-
rons are scattered throughout the ventral portion of lamina
VIII, ventrolaterally in lamina IX, and in the ventral
aspects of lamina VII proximally. No immunolabeling is
observed within the cuneate or gracile fasciculus, the
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dorsal corticospinal tract, the lateral funiculus, or the
ventral funiculus.
In the thoracic spinal cord, there is modest fiber and
terminal staining in laminae I and III, with moderate
numbers of dark neurons in lamina II. The lateral spinal
nucleus contains heavy fiber and moderate cell staining,
with no extension to the lateral funiculus, which is devoid
of immunolabeling. Laminae IV and V have moderate fiber
and terminal labeling, but no immunolabeled neurons are
evident. Moderately immunolabeled fibers and puncta are
seen in lamina VII and in the dorsal part of lamina VIII.
Terminal and fiber labeling in lamina X is strong, with
scattered immunolabeled neurons also present. Immunola-
beled neurons are present in the intermediomedial cell
column near lamina X. Large moderately stained neurons
also are observed in the ventral horn in this region. Cells
are observed primarily in lamina IX, with occasional
smaller, immunolabeled neurons observed in lamina VIII.
DISCUSSION
In situ hybridization and immunohistochemistry results
demonstrate a diffuse distribution of OFQ in the adult
male rat CNS. These findings are in general agreement
with early in situ hybridization studies on the distribution
of the preproorphanin precursor in the rat and mouse
(Houtani et al., 1996; Mollereau et al., 1996b; Nothacker at
al., 1996; Pan et al., 1996; Henderson and McKnight,
1997). In these studies, OFQ precursor mRNA was demon-
strated in several brain areas, including the cortex, stria-
tum, lateral septum, bed nucleus of the stria terminalis,
thalamus, amygdala, hypothalamus, substantia nigra, cen-
tral gray, raphe nuclei, pedunculopontine nucleus, supe-
rior and inferior colliculi, olivary complex, spinal trigemi-
nal nucleus, and spinal cord dorsal horn. There are few
areas of disagreement between the findings in the present
mapping study and initial surveys for mRNA expression.
By using Northern blot analysis of the preproorphanin
precursor in the rat, Mollereau et al. (1996b) demonstrated
specific expression of preproorphanin mRNA in several
brain areas. They found no mRNA expression in the
pituitary, weak expression in the cortex and hippocampus,
and strong mRNA expression in the hypothalamus and
striatum. The strong mRNA expression observed by this
group in the striatum is in contrast to the paucity of mRNA
expression and peptide labeling observed in the striatum
of the rat in our study. In situ analysis by Houtani et al.
(1996) detected orphanin mRNA in the nucleus of the
lateral lemniscus and in the inferior vestibular area, two
brainstem regions in which we found no mRNA or peptide
expression. In general, however, the overall mRNA distri-
bution they observed was similar to ours.
There were very few regions where mismatch occurred
between immunostaining and mRNA expression. In layers
II, III, and V of the temporal cortex; layers II and III of the
occipital cortex; the medial orbital cortex; the medial
anterior olfactory nucleus; the anteroventral nucleus of
the thalamus; the lateral habenula; the subgeniculate
nucleus; the lateral interpeduncular nucleus; medial sub-
nucleus B of the inferior olive; lamina V of the cervical
spinal cord; laminae IIII and VIII of the thoracic spinal
cord; and the dorsal root ganglia, light-to-moderate mRNA
expression was detected, but no neuronal immunolabeling
was seen. This disparity could represent regions where
immunolabeling was not sensitive enough to detect OFQ
peptide production within cell bodies, but it also may
represent regions where preproorphanin mRNA is present
but is not being translated into the OFQ peptide. In
addition, the precursor molecule may be undergoing post-
translational processing, making it unavailable for immu-
nolabeling by using our OFQ sequence. Although an
antiserum directed against a different portion of the
preproorphanin sequence may generate neuronal labeling
in these few regions, the general immunostaining pattern
generated with our OFQ antiserum correlates excellently
with in situ hybridization results. In addition, immunore-
activity generally was not observed in structures that were
devoid of OFQ mRNA expression, the exceptions being
scattered immunolabeled neurons observed in the stria
terminalis, the stratum oriens of region CA2 of Ammon’s
horn, the terete nucleus of the hypothalamus, the central
nucleus of the inferior colliculus, the rostral preolivary
nucleus, the paralemniscal nucleus, and the lateral spinal
nucleus. All of these regions are devoid of mRNA expres-
sion but contain light neuronal immunolabeling.
Colchicine treatment
Colchicine injection into the lateral ventricle markedly
altered OFQ immunohistochemical staining in the rat
brain, allowing us to closely analyze neuronal elements
containing the OFQ peptide. In the untreated animals,
neuronal labeling was observed in several regions (e.g.,
lateral septum, hypothalamus, reticular nucleus of the
thalamus, nucleus of Darkschewitsch, dorsal tegmental
nucleus, nucleus of the solitary tract, nucleus ambiguous),
but intensity of labeling was significantly diminished. In
contrast, fiber and terminal labeling was more pronounced
in untreated rats than in colchicine-treated animals. In
treated animals, fiber and terminal labeling was present
in similar structures, but was diminished. Such a pattern
of immunolabeling is expected in animals treated with an
inhibitor of microtubule-dependent axonal transport, such
as colchicine.
Although it has been used extensively in immunohisto-
chemical mapping studies, recent reports have raised the
possibility that colchicine treatment induces an increase
in mRNA levels for certain neuropeptides in the rat brain
(Cortes et al., 1990; Ceccatelli et al., 1991; Kiyama and
Emson, 1991). If such an effect does occur, then the authors
argue that some mRNA labeling seen in colchicine-treated
animals could represent artifact rather than true mRNA
expression. In our experiences, and in the present study,
we have not found that colchicine treatment produces such
an effect. An excellent correlation was observed between
preproorphanin mRNA distribution in untreated animals
and that of the OFQ peptide in colchicine-treated and
untreated animals. In general, every area that contained
mRNAexpression also demonstrated some degree of immu-
nolabeling, and more importantly, the counter also held
true; in no areas of the rat CNS were immunolabeled
neurons detected where mRNA-expressing cells were not
localized. Our in situ hybridization technique is generally
more sensitive in detecting cell bodies than immunohisto-
chemistry, because it detects not only neurons that synthe-
size OFQ but also those that have the potential to synthe-
size OFQ peptide. Messenger RNA expression, therefore,
is more perceptible than immunolabeling in the CNS in
those animals that were the least stressed of all (noncolchi-
cine treated and nonperfused). Colchicine treatment, al-
though it can provide a valuable benefit in detecting
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OFQ-containing cell bodies, produced no neuronal labeling
in areas devoid of mRNA expression in our hands.
Antiserum specificity
The anti-OFQ antiserum generated for use in the pre-
sent study has not been utilized in any prior studies. After
detailed analysis of several bleeds from both rabbits,
affinity purification was performed on two bleeds. Antisera
from bleed 6, animal 217, was chosen for this study based
on quality and reliability of staining and on specificity of
immunolabeling. This antiserum was noted to be quite
specific in most areas studied. By preabsorbing the OFQ
antiserum with a 25-µM concentration of OFQ peptide
prior to tissue application, immunolabeling was blocked
completely in virtually every CNS structure analyzed.
However, there were some exceptions that warrant discus-
sion. In the forebrain, there is very strong fiber labeling in
the ventral lateral septum. In preabsorption control stud-
ies, very small numbers of these fibers are not blocked
completely, although they remain very lightly stained.
Lateral to the paraventricular nucleus of the hypothala-
mus, there is a cluster of very intensely immunolabeled
neurons with scattered fibers. In preabsorption controls,
fiber labeling in this region is blocked completely, but
several of the neurons remain immunolabeled. Although
they are not blocked completely, the numbers of neurons
labeled are very few, and the intensity of labeling is very
light. Outside of the cerebellum (discussed below), there
are no other structures in the CNS in which immunolabel-
ing is not blocked completely (Fig. 3). The two regions
(discussed above) might represent cross reactivity of the
antiserum with other peptides in these areas, but this is
unlikely. If such cross reactivity did indeed exist, then one
would assume not only that there would be somewhat
stronger immunoreactive labeling in preabsorption con-
trols but also that there would be labeling in several other
CNS regions. Because this unblocked labeling was found
only in areas of intense immunolabeling under regular
conditions, the OFQ antiserum may not be blocked 100%
by using a 25-µM concentration of peptide, detecting
peptide in only these regions.
In the cerebellum, immunostaining observed in the
fastigial nucleus was blocked completely in preabsorption
controls. Specific mRNA expression also was observed in
this nucleus. In the cerebellar lobules, OFQ expression is
not so clear. Scattered mRNA-containing neurons were
observed in the granular layer and were shown to be
specific in RNase and sense control studies, but Purkinje
cells were found to have no prepro-OFQ mRNA content. In
immunohistochemical studies, the cerebellum contained
numerous, large, immunoreactive neurons within the Pur-
kinje cell layer of the cerebellum. These neurons were seen
in all lobules and were unblocked completely in preabsorp-
tion control studies. These neurons were present in colchi-
cine-treated and untreated animals, so this staining was
not an effect of colchicine. In addition, other CNS regions
with large neuronal elements (e.g., the red nucleus, cranial
nerve motor nuclei) did not demonstrate such staining, so
this was not an artifact of large neuron size. It is possible
that, specifically within the cerebellar hemispheres where
this unique labeling pattern is found, there may be some
elements that cross react with nonorphanin-specific anti-
bodies within the OFQ antiserum. In this most likely
scenario, 1) this cross reactivity is specific to the cerebellar
hemisphere and is not even seen in the cerebellar deep
nuclei, 2) it is not colchicine-dependent, and 3) it is not
seen in any fiber or terminal elements. The immunolabel-
ing pattern in the cerebellar hemisphere, therefore, is
treated as nonspecific artifact in this study. Based on the
remainder of our preabsorption controls and on their
exceptional correlation with in situ expression, we are
confident that all other immunolabeling patterns in this
study are specific for the OFQ peptide.
Comparisons with endogenous
opioid systems
The distributions of the endogenous opioid peptide pre-
cursors, proopiomelanocortin, proenkephalin, and pro-
dynorphin, have been studied in detail (Kachaturian et al.,
1985), as has the distributions of the corresponding µ, k,
and d opioid receptors (Mansour et al., 1993, 1994, 1995a,b,
1996). Since its discovery, the ORL1 receptor has been
shown to differ markedly from the known opioid receptors
not only in its structure and interactions with known
opioid agonists (Meng et al., 1996; Sim et al., 1996; Ma et
al., 1997) but also in its distribution (Chen et al., 1994;
Fukuda et al., 1994; Lachowicz et al., 1994; Anton et al.,
1996). Likewise, the distribution of the endogenous ligand
for the ORL1 receptor, OFQ, as demonstrated in this study,
is distinct from that of other opioid peptides. Close analy-
sis of the distribution of these peptide-receptor systems,
however, points to numerous CNS regions in which the
opioid and orphanin systems may interact.
Proopiomelanocortin and the m receptor
Proopiomelanocortin, which gives rise to the endog-
enous opioid, b-endorphin, has a very limited neuronal
distribution, with cell bodies encountered only in the
arcuate nucleus, anterior pituitary, and nucleus of the
solitary tract. Its fiber distribution is more widespread,
with most pronounced fiber labeling found in the bed
nucleus of the stria terminalis, central and medial nuclei
of the amygdala, dorsomedial and arcuate nuclei of the
hypothalamus, paraventricular nucleus of the thalamus,
central gray, the raphe nuclear complex, lateral parabra-
chial nucleus, mesencephalic trigeminal nucleus, and
nucleus of the solitary tract (Kachaturian et al., 1985). In
contrast, the µ receptor has a much broader distribution
pattern, with heavy receptor binding observed in fibers
and perikarya within the neocortex, striatum, nucleus
accumbens, anterior cortical and medial amygdala nuclei,
most thalamic nuclei, the presubiculum, dentate gyrus,
medial mammillary nucleus, substantia nigra pars com-
pacta, central gray, superior colliculus, inferior colliculus,
parabrachial nucleus, dorsal and paramedian raphe, ra-
phe magnus, pontine reticular formation, nucleus ambigu-
ous, nucleus of the solitary tract, spinal trigeminal nucleus,
and substantia gelatinosa of the dorsal horn of the spinal
cord (Mansour et al., 1995a).
In the rat brain, the arcuate nucleus of the hypothala-
mus and nucleus of the solitary tract are the only struc-
tures in which cell bodies may express both OFQ (Figs.
10A,B, 20C,D) and b-endorphin peptides, regions in which
orphanin may play a modulatory role on b-endorphin-
containing neurons. The arcuate nucleus has been shown
to contain abundant orphanin receptors, and OFQ has
recently been shown to inhibit b-endorphin neurons and
secretory cells in the arcuate through activation of inward
K1 currents (Wagner et al., 1998). Within the bed nucleus
of the stria terminalis, central and medial nuclei of the
538 C.R. NEAL, JR. ET AL.
amygdala, dorsomedial and arcuate nuclei of the hypothala-
mus, paraventricular nucleus of the thalamus, central
gray, dorsal raphe, lateral parabrachial nucleus, and
nucleus of the solitary tract, regions with abundant b-en-
dorphin fibers, orphanin fiber immunolabeling is robust.
Orphanin-like receptor immunoreactivity is present in
these areas as well (Anton et al., 1996), providing opportu-
nity for OFQ interaction with the proopiomelanocortin
system. Within the dentate gyrus, µ-receptor immunoreac-
tivity has been shown to localize to interneurons within
the granule cell layer (Mansour et al., 1995a), very similar
to what was demonstrated for OFQ in this study (Fig.
13B). Mu-Receptor immunoreactivity in cell bodies within
the central gray, raphe nuclei, lateral parabrachial nucleus,
nucleus ambiguous, solitary nucleus, and lamina II of the
dorsal horn (Mansour et al., 1995a) also localizes in a
distribution very similar to what was observed for orpha-
nin in this study (Figs. 3E, 16A,B, 17D, 18, 20C,D, 21D). In
addition, OFQ also is localized in neurons in the pars
compacta of the substantia nigra (Fig. 8D), another area in
which the µ receptor is localized within cell bodies and
binding is dense. Expression of OFQ within cell bodies that
coexpress the µ-receptor protein and have dense µ binding
would provide strong evidence for possible µ modulation of
this peptide within these structures. Other areas in which
OFQ is strongly expressed and µ-receptor expression is
robust include the medial amygdaloid nucleus (Fig. 12A,B)
and the paraventricular nucleus of the thalamus.
Prodynorphin and the k receptor
Prodynorphin-containing cell bodies are expressed pri-
marily in the striatum, dentate gyrus, central nucleus of
the amygdala, paraventricular, supraoptic, ventromedial
and arcuate nuclei of the hypothalamus, lateral hypotha-
lamic area, anterior pituitary, substantia nigra pars reticu-
lata central gray, parabrachial nucleus, lateral reticular
nucleus, nucleus of the solitary tract, spinal trigeminal
nucleus, and dorsal horn of the spinal cord. Fibers contain-
ing prodynorphin are very heavy in the forebrain in
nucleus accumbens, ventral pallidum and globus pallidus,
CA3 area of Ammon’s horn, paraventricular nucleus of the
hypothalamus, and pars reticulata of the substantia, but
they are less dispersed in the brainstem, with moderate
fiber plexuses found in the central gray, the raphe nuclear
complex, parabrachial nucleus, solitary nucleus, spinal
trigeminal nucleus, and dorsal horn (Kachaturian et al.,
1985). The densest concentrations of k-receptor binding
and cell immunolabeling are found in the nucleus accum-
bens, olfactory tubercle, medial preoptic area, bed nucleus
of the stria terminalis, medial nucleus of the amygdala,
paraventricular nucleus of the thalamus, several hypotha-
lamic nuclei, including the supraoptic, paraventricular,
ventromedial, and medial mammillary nuclei, superior
colliculus, ventral tegmental area, substantia nigra, cen-
tral gray, dorsal raphe, parabrachial nucleus, dorsal teg-
mental nucleus, caudal nucleus of the solitary tract, and
spinal trigeminal nucleus (Mansour et al., 1995b, 1996).
There are several regions in which orphanin-containing
cell bodies could coexist or colocalize with dynorphin-
containing neurons, including the dentate gyrus (Fig.
13B), central nucleus of the amygdala (Fig. 12C,D), para-
ventricular and arcuate nuclei of the hypothalamus (Fig.
10), lateral hypothalamic area, pars reticulata of the
substantia nigra (Fig. 3C), central gray (Fig. 16A,B),
interpeduncular nucleus (Fig. 15A,B), paramedian raphe
and raphe magnus (Fig. 18), lateral reticular nucleus,
solitary nucleus (Fig. 20C,D), spinal trigeminal nucleus,
(Fig. 21A,B) and dorsal horn of the spinal cord (Fig. 21C,
D). Within the CA3 region of Ammon’s horn, the central
gray, parabrachial nucleus, caudal spinal trigeminal
nucleus, nucleus of the solitary tract, and dorsal horn of
the spinal cord, orphanin is strongly expressed in cells and
fibers, and the ORL1 receptor also is intensely immunola-
beled (Anton et al., 1996). These regions also contain
robust dynorphin fiber labeling and moderate k-receptor
localization and binding, providing possible sites of dynor-
phin and orphanin system interactions. The core of the
nucleus accumbens (Fig. 6C,D), medial preoptic area (Fig.
9F), bed nucleus of the stria terminalis (Fig. 9C,D), para-
ventricular and ventromedial nuclei of the hypothalamus,
median eminence (Fig. 1B), and medial nucleus of the
amygdala (Fig. 12A,B) contain abundant OFQ fiber and
cell staining and robust k-receptor localization and bind-
ing. These distribution patterns also provide evidence for
possible k modulation of OFQ within these structures. It is
of interest to note that the substantia (nigra) pars reticu-
lata contains a very dense prodynorphin cell and fiber
plexus. Although this structure contains only light k
binding and receptor content, it possesses a moderate
amount of OFQ peptide and abundant ORL1-containing
fibers, providing a likely milieu for orphanin-opiate inter-
action in this basal ganglia structure.
Proenkephalin and the d receptor
Proenkephalin is the most widely distributed of the
endogenous opioid peptides (Kachaturian et al., 1985),
with the densest concentration of enkephalin-containing
cell bodies in the cingulate and neocortex, anterior olfac-
tory nucleus, olfactory tubercle, piriform cortex, striatum,
nucleus of the diagonal band, bed nucleus of the stria
terminalis, central nucleus of the amygdala, hippocampal
formation, paraventricular, arcuate, and ventromedial nu-
clei of the hypothalamus, central gray, interpeduncular
nucleus, inferior colliculus, raphe nuclei, parabrachial
nucleus, dorsal tegmental nucleus, medial vestibular
nucleus, lateral reticular nucleus, nucleus of the solitary
tract, spinal trigeminal nucleus, and dorsal horn of the
spinal cord. Enkephalin-containing fibers are most pro-
nounced in the nucleus accumbens, globus pallidus, hippo-
campal formation, ventromedial nucleus of the hypothala-
mus, central gray, solitary nucleus, spinal trigeminal
nucleus, and dorsal horn. Delta-Receptor localization and
binding are most prominent the neocortex, anterior olfac-
tory nucleus, nucleus accumbens, striatum, olfactory tu-
bercle, medial and basolateral nuclei of the amygdala,
hippocampal formation, interpeduncular nucleus, pontine
nuclei, nucleus of the trapezoid body, lateral reticular
nucleus, spinal trigeminal nucleus, and dorsal horn of the
spinal cord (Mansour et al., 1995b).
Enkephalin-containing neurons have a high likelihood
of colocalizing or coexpressing with OFQ in several struc-
tures in which orphanin-containing neurons are present,
including the cingulate and piriform cortices (Fig. 6A),
diagonal band, bed nucleus of the stria terminalis (Fig.
9C,D), central nucleus of the amygdala (Fig. 12C,D), hippo-
campal formation (Fig. 13), paraventricular and arcuate
nuclei of the hypothalamus (Fig. 10), central gray (Fig.
16A,B), interpeduncular nucleus (Fig. 15A,B), paramedian
raphe and raphe magnus (Fig. 18), lateral reticular nucleus
(Fig 20E), solitary nucleus (Fig. 20C,D), spinal trigeminal
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nucleus (Fig. 21A,B), and dorsal horn of the spinal cord
(Fig. 21C,D). Enkephalin-containing fibers in the nucleus
accumbens, hippocampus ventromedial nucleus of the
hypothalamus, central gray, interpeduncular nucleus, soli-
tary nucleus, and dorsal horn are within regions where
orphanin-containing fibers also are present. These regions
also contain heavy ORL1 immunoreactivity (Anton et al.,
1996) and may be areas of orphanin modulation of enkepha-
lin activity. Although not yet demonstrated in the brain,
OFQ has been shown to modulate enkephalin release in
myenteric plexus preparations (Gintzler et al., 1997). The
neocortex, cingulate cortex, nucleus accumbens, ventrome-
dial nucleus of the hypothalamus, medial nucleus of the
amygdala, interpeduncular nucleus, spinal trigeminal nucleus,
and substantia gelatinosa of the dorsal horn contain strong
OFQ neuronal and/or fiber labeling as well as numerous
neurons with d-receptor protein and robust binding. The
strong overlapping distribution of the d receptor with
orphanin fibers in these nuclei provides sites for enkepha-
lin or other opioid modulation of the orphanin peptide.
Functional considerations
Comparison with ORL1 receptor distribution. In
their detailed analysis of the distribution of the ORL1
receptor, Anton et al. (1996) did not include an analysis of
orphanin receptor mRNA distribution but, rather, focused
on the distribution of the receptor protein. Similar to our
findings with OFQ, those authors found that the orphanin
receptor was distributed diffusely the rat CNS. In their
study, Anton et al. reported very few neurons containing
ORL1 receptor immunoreactivity, with virtually all immu-
nostaining confined to fibers and puncta. Orphanin recep-
tor immunoreactivity was observed within somata in the
dentate gyrus of the hippocampus, the red nucleus, the
pontine reticular nucleus, gigantocellular and paragiganto-
cellular reticular nuclei, lamina IX of the spinal cord, and
the central cervical nucleus. This is in sharp contrast to
the diffuse distribution of OFQ-containing perikarya re-
ported in our analysis. Densest ORL1 receptor fiber and
terminal staining was observed in the neocortex, cingulate
cortex, piriform cortex, entorhinal cortex, dorsal and ven-
tral pallidum, triangular and medial septum, medial pre-
optic area, central and medial nuclei of the amygdala,
cortical amygdala, Ammon’s horn, subiculum, anterior
olfactory nucleus, claustrum, endopiriform nucleus, mam-
millary bodies, parafascicular and posterior thalamic nu-
clei, substantia nigra, ventral tegmental area, interpedun-
cular nucleus, central gray, dorsal raphe, trigeminal motor
nucleus, suprafacial nucleus, nucleus ambiguous, nucleus
of the solitary tract, dorsal nucleus of the vagal nerve,
hypoglossal nucleus, parvocellular reticular nucleus of the
medulla, and lamina II of the spinal cord. Lighter fiber and
terminal labeling was observed in numerous other struc-
tures diffusely throughout the CNS. Mismatch between
the receptor and neurotransmitter distributions like what
we observed with the orphanin system is not unique and
has been demonstrated extensively in the opioid peptide
and receptor systems (Kachaturian et al., 1985; Mansour
et al., 1995b). When comparing ORL1 receptor immunohis-
tochemical distribution with OFQ peptide distribution, it
is clear that they differ markedly in their anatomical and
structural localization. However, on close analysis, mul-
tiple anatomical circuits become evident in which peptide-
receptor interactions may provide insights into functional
roles for this new orphanin system.
Limbic-hypothalamic-pituitary adrenal axis. The
function of the limbic-hypothalamic-pituitary adrenal (L-
HPA) axis has been studied extensively, and much is
known concerning its role at the behavioral, anatomic, and
cellular levels (Herman et al., 1996; Herman and Cullinan,
1997). It is generally accepted that two types of stressors
are involved in the initiation of the stress response: those
involving an immediate physiologic threat (systemic stress-
ors) and those requiring interpretation by higher brain
structures (processive stressors). Whereas processive
stressors are likely channeled through limbic forebrain
circuits involved in the L-HPA axis and then to the
paraventricular nucleus of the hypothalamus, systemic
stressors probably are relayed directly to the paraventricu-
lar nucleus through brainstem cholinergic neurons. The
L-HPA axis is a steroid-sensitive system (Herman and
Cullinan, 1997) because many of these stress-related
nuclei are sensitive to circulating glucocorticoid levels.
Several forebrain nuclei are known to be involved in
stress-excitatory circuits. Of these, the medial, central,
and posterior medial cortical nuclei of the amygdala and
the lateral bed nucleus of the stria terminalis possess both
mineralocorticoid receptors and OFQ-containing neuronal
and fibers elements. Glucocorticoid receptors also are
found in the central nucleus. Stress-inhibitory circuits
include the medial bed nucleus of the stria terminalis, the
medial preoptic area, and the dorsomedial, ventromedial,
arcuate and suprachiasmatic nuclei of the hypothalamus.
Mineralocorticoid receptors are found in the medial preop-
tic area, and glucocorticoid receptors are found in the
medial preoptic area, arcuate nucleus, bed nucleus of the
stria terminalis, and ventromedial nucleus. With the
exception of the suprachiasmatic nucleus, OFQ immunola-
beling and mRNA expression are seen in all of these nuclei.
Other forebrain regions with direct input into this cir-
cuitry are the ventral subiculum, prefrontal cortex, and
hippocampal formation, all of which have orphanin-
containing neurons and glucocorticoid receptors.
There is considerable evidence supporting a role for
brainstem catecholaminergic neurons in the regulation of
the stress axis (Plotsky et al., 1989). Their action is on
L-HPA activation and appears to be stimulatory by way of
a-1-adrenergic receptors. Direct noradrenergic input onto
neurons in the parvocellular paraventricular nucleus is
through the ventral noradrenergic bundle, which is sup-
plied primarily by the A2, C1, C2, and C3 cell groups in the
brainstem. Orphanin peptide is not expressed in these
regions, making it unlikely that OFQ plays a modulatory
role in these direct inputs. The locus coeruleus, one of the
most stress-responsive nuclei in the brain (Herman et al.,
1996), is thought to modulate L-HPA activation indirectly
through multisynaptic connections with forebrain regions,
such as the prefrontal cortex, hippocampus, and amyg-
dala. Orphanin mRNA and peptide is localized in all of
these regions, providing possible regions in which OFQ
may modulate noradrenergic input into the stress axis. A
role for serotonin in L-HPA activation is supported by the
finding that destruction of serotonin neurons in the dorsal
raphe reduces corticosterone and adrenocorticotropin re-
sponses to stressful stimuli (Herman et al., 1996), and
neurons within the raphe complex provide direct projec-
tions to the parvocellular paraventricular nucleus. Orpha-
nin peptide and mRNA are localized within many neuronal
and/or fiber elements within the raphe system, allowing
540 C.R. NEAL, JR. ET AL.
involvement of OFQ in the modulation of brainstem sero-
tonergic activation of the L-HPA axis.
At present, little has been shown behaviorally to support
an role for orphanin in the stress response. Recently, Jenck
et al. (1997) demonstrated that OFQ can modulate anxiety
states generated by acute stress. Those authors concluded
that OFQ may act as an anxiolytic in certain stressful
circumstances. Orphanin indeed may play a modulatory
role on the stress response through inhibitory effects on
L-HPA activation. If so, then its role as an anxiolytic agent
could be explained.
Learning and memory. The hippocampal formation
is not only intimately involved in the function of the L-HPA
axis, it is also a critical structure in learning and memory.
OFQ is found throughout the hippocampal formation, and
OFQ-containing neurons are also observed in the entorhi-
nal cortex, which has direct projections to the entire
hippocampal formation. In addition, ORL1 receptor immu-
noreactivity is strong in all hippocampal regions (Anton et
al., 1996). Orphanin has been reported to reversibly in-
hibit voltage-gated calcium channels in pyramidal neu-
rons from areas CA1 and CA3 (Knoflach et al., 1996) and to
inhibit synaptic transmission and long-term potentiation
in area CA1 of Ammon’s horn and the dentate gyrus (Yu et
al., 1997). The latter effect is thought to be postsynaptic in
nature (Yu and Xie, 1998). Microinjections of OFQ into the
CA3 region of adult rats have been shown to impair spatial
learning (Sandin et al., 1997). These findings remain
controversial, because the effects of orphanin on motor
behavior were not taken into account (see below). How-
ever, in support of the findings by Sandin et al., recent
studies on knockout mice lacking the orphanin receptor
demonstrated enhancement of spatial attention in the
water-finding test (Mamiya et al., 1998) and facilitation of
long-term potentiation and memory (Manabe et al., 1998).
Initial studies support a role for this peptide in learning
and memory, and its distribution throughout the hippocam-
pal formation and entorhinal cortex supports this concept
as well.
Motor systems. Orphanin-containing neurons are
located in the globus pallidus, entopeduncular nucleus,
and substantia nigra, and significant OFQ-containing
fibers are found in these structures and in the striatum. In
addition, the lateral bed nucleus of the stria terminalis, a
component of the extended central amygdaloid complex
(Alheid et al., 1995), has abundant OFQ peptide content
and has direct projections to the retrorubral field, ventral
tegmental area, and substantia nigra, pars compacta.
These structures possess abundant ORL1 receptor density
(Anton et al., 1996) and give rise to major dopaminergic
projections. Early behavioral effects observed with central
administration of this peptide may reflect a conceivable
role of OFQ in the modulation of gross locomotive behavior.
OFQ also is localized within brainstem structures that
direct several aspects of fine motor control and balance,
including vestibular nuclei, deep cerebellar nuclei, and the
inferior olive. Proprioceptive input from the dorsal col-
umns of the spinal cord is integrated in the dorsal olivary
nucleus, which relays information to the cerebellar vermis,
which, in turn, has very strong inputs into the medial
(fastigial) cerebellar nucleus. The fastigial nucleus projects
heavily to nuclei involved with visual integration and to
the spinal vestibular nucleus. Orphanin-containing cell
bodies are expressed consistently throughout this cir-
cuitry, and, although ORL1 immunoreactivity is light in
these areas (Anton et al., 1996), orphanin binding is
prominent in many of these structures (personal observa-
tions). Input into the principal olivary nucleus originates
primarily in visual integration areas and association corti-
ces. This nucleus projects to the lateral cerebellar hemi-
spheres, which have strong input to all vestibular nuclei
except the lateral nucleus. Orphanin peptide content is
very strong in the visual nuclei, which project to the
principal olivary nucleus (nucleus of Darkschewitsch, inter-
stitial nucleus of the medial longitudinal fasciculus, and
medial accessory oculomotor nucleus), as well as within
the principal olivary nucleus itself. The vestibular nuclei
provide integration of proprioceptive input and provide
efferents from the lateral vestibular nucleus to the inferior
olive and from the spinal vestibular nucleus to the cerebel-
lum and reticular formation. The medial and superior
vestibular nuclei have projections to the cerebellum, spi-
nal cord, thalamus, and lateral paragigantocellular reticu-
lar nucleus.
The effects of orphanin on gross motor function are
somewhat controversial and are largely unknown at this
point. Orphanin has been implicated in producing hypolo-
comotion in rats (Devine et al., 1996a) and in stimulating
locomotion and exploratory behavior in mice (Florin et al.,
1996). Many early behavioral tests using intraventricular
orphanin may have been confounded by the fact that
higher doses of this peptide have been shown to seriously
disrupt motor behavior in adult rats (D.P. Devine, personal
communication). Indeed, OFQ is localized within many
structures in the CNS that are intimately involved in
locomotion, balance, and proprioception. It remains to be
determined exactly what role orphanin plays in motor
function, but the presence of OFQ in the basal ganglia and
in the vestibular and visual motor systems supports a
modulatory role for this peptide in these related behaviors.
The effects of this peptide on motor function should be
considered when analyzing other behavioral effects.
Reinforcement and reward. The nucleus accumbens
has been implicated in a number of functions, including
drug reinforcement and locomotor behavior (Koob et al.,
1991). Little is known concerning possible motivational or
reward effects of OFQ in relation to this region. Rats have
been shown to develop tolerance to locomotor effects
induced by orphanin (Devine et al., 1996a), but they failed
to demonstrate conditioned place preference when given
intraventricular injections of this peptide (Devine et al.,
1996b). In addition, it has been reported that injections of
OFQ into the lateral ventricle of the rat suppresses
dopamine release in the nucleus accumbens (Murphy et al,
1996). Orphanin is strongly expressed in several struc-
tures involved in this circuitry, including the substantia
nigra and the ventral tegmental area. These regions
contain direct projections to the nucleus accumbens and
ventral pallidum, both of which have abundant ORL1
receptor (Anton et al., 1996). The inability to generate
conditioned place preference or aversion in earlier studies
in the rat may have been limited by locomotor effects of
this peptide (D.P. Devine, personal communication), and
the abundance of OFQ within this mesoaccumbens cir-
cuitry still may indicate a modulatory role for this peptide
in reinforcement behaviors.
One particular reinforcing behavior that appears to be
influenced by the accumbens nucleus is that of feeding
behavior. Feeding as a behavioral act is complicated,
requiring several somatomotor and autonomic events re-
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lated to searching for and handling of food, eating, and
digesting. This process involves multiple CNS circuits that
are involved in the integration of olfactory, visual, and
auditory information and many brainstem centers that are
involved in the acts of mastication and digestion. The
lateral septum, a region with high OFQ content, has direct
projections to the medial hypothalamus and the lateral
hypothalamic area. It has been postulated that these
structures are central in the initiation and control of food
intake (King and Nance, 1986). In addition, some mesoac-
cumbens-lateral hypothalamic interactions may be more
central in motivating effects of food intake. A recent report
by Cabeza de Vaca and Carr (1998) demonstrated a
definite enhancement in the central rewarding effect of
abused drugs in animals undergoing food restriction.
Although the nucleus accumbens is thought to be central
in the mechanism, those authors also argue for a major
role of the lateral hypothalamus, a region with abundant
orphanin content.
Pomonis et al. (1996) initially demonstrated that injec-
tions of OFQ into the lateral ventricle of the rat stimulated
feeding to a degree similar to that seen with injection of
other opiates. This response however, was blocked by
naloxone, making it more likely that it may have been an
opiate-driven event. More recently, Stratford et al. (1997)
demonstrated that injections of orphanin into the ventro-
medial hypothalamic nucleus or the nucleus accumbens
increased food intake in rats. By using small doses of
orphanin (2.5–25 nM), they demonstrated orphanin-
specific stimulation of this motivational behavior with
injections into both regions. The role of OFQ in stimulation
of feeding behavior gains further support in a recent study
by Leventhal et al. (1998), which demonstrates a reduction
of OFQ-induced hyperphagia by central administration of
an ORL1 antisense probe. Much remains to be answered
concerning the possible role of OFQ in mechanisms of
motivation and reinforcement. However, early behavioral
findings, coupled with the presence of OFQ and its ORL1
receptor to varying degrees within many structures in-
volved in this circuitry, support involvement of the orpha-
nin system.
Sexual behavior. The anatomic distribution of OFQ
also argues for a possible functional role in sexual behavior
and sexually dimorphic pathways. Evidence for sexual
dimorphism was first reported in the medial preoptic area
by Gorski et al. (1980). Sexual dimorphism emerges early
in development, is related to differences in neuronal
production, and appears to be regulated by circulating
gonadal steroids (Jacobson and Gorski, 1981; Davis et al.,
1996). A steroid-sensitive, enkephalinergic sexual dimor-
phism has also been described in the medial preoptic
region (Watson et al., 1986; Simerly et al., 1988). Other
forebrain nuclei that have major connections with the
medial preoptic area also demonstrate sexual dimorphism,
including the medial amygdala (Nishizuka and Arai, 1983),
medial and lateral parts of the bed nucleus of the stria
terminalis (Guillamon et al., 1988), and several hypotha-
lamic nuclei, including the arcuate nucleus, ventromedial
nucleus, and tuberomammillary nucleus (Urban et al.,
1993; Borisova et al., 1996; Gonzales et al., 1996). The
circuitry that is involved primarily in the medial preoptic
area, bed nucleus of the stria terminalis, and medial
nucleus of the amygdala is not only sexually dimorphic,
but it also has been shown to be critical for normal sexual
behavior in the male hamster (Neal and Newman, 1989).
The medial preoptic area also shares inputs with the
arcuate and ventromedial nuclei of the hypothalamus.
These limbic regions contain some of the highest amounts
of orphanin in the forebrain. Furthermore, the lateral
septum, which contains abundant orphanin peptide and
mRNA expression, also is known to possess androgen and
estrogen receptors and vasopressin immunoreactivity. This
nucleus is also sexually dimorphic and sex-hormone sensi-
tive (Jakab and Leranth, 1995). The lateral septum has
profound hypothalamic projections and receives concen-
trated input from the hippocampal formation, a region
known to be sexually dimorphic (Madeira et al., 1991).
What role orphanin plays in sexual dimorphism or in
sexual behavior is not known. However, its heavy content
throughout circuitry that is not only sexually dimorphic
but also intimately involved in sexual behavior makes it
likely that orphanin plays a major role in the development
or maintenance of this behavior. Supporting this notion, it
has been reported recently that OFQ microinjections into
the ventromedial nucleus of the hypothalamus facilitate
lordosis in female rats (Sinchak et al., 1997).
Pain perception. Several studies have demonstrated
a modulatory role for orphanin in pain perception, al-
though its effects on the pain response remain controver-
sial (Henderson and McKnight, 1997). Studies to date
have shown that orphanin plays an important modulatory
role in pain perception, producing analgesia in some
models (King et al., 1997; Rossi et al., 1997; Tian et al.,
1997a,b; Yamamoto et al., 1997) and antagonizing analge-
sia in others, tempting some to depict its actions as
antiopioid (Grisel et al., 1996; Mogil et al., 1996a,b; Xu et
al., 1996; Dawson-Basoa and Gintzler, 1997; Heinricher et
al., 1997; Morgan et al., 1997; Jhamandas et al., 1998).
OFQ also has been implicated as an antagonist of mor-
phine analgesia (Hao et al., 1997; Tian et al., 1997b; Zhu et
al., 1997), although morphine analgesia has been demon-
strated in mice lacking the ORL1 receptor gene. It is
interesting to note that these ORL1-deficient animals
were unable to develop tolerance to the analgesic affects of
morphine after repeated doses (Ueda et al., 1997). Recent
studies have also implicated orphanin in pain induction
from nonnoxious stimuli (allodynia; Okuda-Ashitaka et
al., 1996; Hara et al., 1997; Minami et al., 1997).
Much is known concerning the ascending and descend-
ing pain pathways, particularly those involving endog-
enous opioid systems (Mansour et al., 1995b). In this
context, somatosensory inputs from laminae I and II of the
dorsal horn of the spinal cord and from the spinal trigemi-
nal nucleus ascend directly to the posterior and centrolat-
eral nuclei of the thalamus and then are relayed to the
somatosensory cortex. This ascending information is modu-
lated at many levels, including, initially, within the
substantia gelatinosa, and by passing inputs from the
reticular formation. Descending information from the so-
matosensory cortex ultimately terminates in the dorsal
horn of the spinal cord, relaying feed-back information for
nociception modulation. These inputs are not direct and
arrive at the spinal cord by way of the central gray, raphe
magnus, and alpha division of the gigantocellular reticular
formation (Mansour et al., 1995b). These projections are
modulated further in passing by inputs from the dorsal
raphe, median raphe, lateral parabrachial nucleus, and
reticular formation. It has long been known that endog-
enous opioid peptides and receptors strongly influence
these nociceptive pathways. It is also important to note
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here that OFQ is physically present along all parts of this
pain circuitry as well, with OFQ-containing neurons and
fibers found in the central gray, the raphe nuclei, the
lateral parabrachial nucleus, the reticular formation nu-
clei, the spinal trigeminal nucleus, and the superficial
laminae of the spinal cord.
Although colocalization has not been demonstrated,
OFQ has been shown to have an overlapping distribution
with opioid peptides in several pain modulatory regions,
including the dorsal horn of the spinal cord, spinal trigemi-
nal nucleus, raphe nuclei, locus coeruleus, and central
gray (Schulz et al., 1996). In addition, there is an accumu-
lating body of evidence supporting modulatory influences
of OFQ on painful inputs into the CNS as both an agonist
and an antagonist to analgesia. It is presently hypoth-
esized that the outer two-thirds of the substantia gelati-
nosa play a major role in the modulation of nociception,
and this region contains a myriad of various neurotransmit-
ters, including opioid peptides (Ribeiro-da-Silva, 1995).
Orphanin immunoreactivity has been demonstrated quan-
titatively in lamina II, and OFQ-containing fibers parallel-
ing endogenous opioids have been identified (Riedl et al.,
1996; Schuligoi et al., 1997). Cell recordings from substan-
tia gelatinosa neurons have shown that exogenous OFQ
depresses excitatory postsynaptic potentials evoked by
stimulation of dorsal root ganglia (Lai et al., 1997; Liebel
et al., 1997). Intrathecal orphanin also has been shown to
inhibit C-fiber-evoked discharge of dorsal horn neurons
(Stanfa et al., 1996). These studies clearly support a role
for orphanin inhibition of lamina II neurons within the
spinal pathway of the rat spinal cord.
Opioid- and orphanin-containing cell bodies also are
numerous in the rostral ventromedial medulla, a region in
which the ORL1 receptor also has been identified (Anton et
al., 1996). This region includes reticular formation and
raphe neurons that are known to have an antinociceptive
influence to noxious stimuli. Electrophysiologic and phar-
macologic studies in this region have demonstrated an
inhibitory role of OFQ on the firing of these neurons in the
presence of morphine activation, leading the authors to
hypothesize that OFQ exerts an ‘‘antiopioid’’ effect by
suppressing firing of these cells (Heinricher at al., 1997).
Finally, microinjections of morphine and OFQ into the
central gray have demonstrated that OFQ attenuates
morphine-induced analgesia in awake rats (Morgan et al.,
1997). Separate studies have shown that microinjections of
OFQ alone demonstrate inhibitory actions on central gray
neurons (Vaughan et al., 1997).
In conclusion, the anatomic localization of OFQ within
important structures along the ascending and descending
pain pathways, its proximity to the endogenous opioid
peptide systems, and mounting physiologic and behavioral
evidence appear to support a major role for orphanin in
pain modulation. It is important to note that it has been
demonstrated recently that the ORL1 and µ antisera label
different fibers in pain-processing regions of the rat brain
(Monteillet-Agius et al., 1998). Therefore, it is most likely
that ORL1 and µ influences on pain perception occur
through predominantly different fiber systems.
Autonomic and physiologic functions. There have
been several studies supporting a role for orphanin in
control of basic autonomic and physiologic mechanisms,
including cardiovascular control (Gumusel et al., 1997;
Champion and Kadowitz, 1997a, b; Champion et al., 1997
and water and electrolyte balance (Kapusta et al., 1997).
Application of OFQ onto arterial rings from the cat demon-
strates vasorelaxant properties (Gumusel et al., 1997), and
this peptide has been shown to induce hypotension (Cham-
pion and Kadowitz, 1997a,b) and to decrease cardiac
output (Champion et al., 1997) in rats. Although the role of
OFQ in autonomic circuitry is not clear, L-glutamate
stimulation of the zona incerta has been shown to decrease
heart rate and blood pressure (Spencer et al., 1988) in the
rat. Intraventricular administration of OFQ also has been
shown to induce diuresis and antinatriuresis in the rat,
implicating this peptide in the central control of water
balance and possibly in the regulation of blood pressure
(Kapusta et al., 1997). Peripheral intravenous infusion of
orphanin also produces diuresis and inhibits salt wasting,
implying that this effect also may have a peripheral
component. It should be noted, however, that the OFQ
doses used by Kapusta et al. were magnitudes higher than
those used in studies that elicited analgesic, nociceptive,
and motor effects. In support of a role for OFQ in water
balance, the ORL1 receptor is highly expressed in the
supraoptic and paraventricular nuclei of the hypothala-
mus (Anton et al., 1996). The diuretic and antinatriuretic
effects of OFQ may be vasopressin mediated, because OFQ
has been shown to inhibit firing of vasopressin-containing
neurons in the supraoptic nucleus of the hypothalamus
(Doi et al., 1998), or it may involve peripheral modulation
of renal sympathetic nerves.
Orphanin involvement in noradrenergic and serotoner-
gic systems also may play a role in cardiovascular control
and fluid balance. Treatments that increase central extra-
cellular serotonin increase sodium excretion, and renal
denervation attenuates natriuresis produced by intraven-
tricular administration of serotonin (Montes and Johnson,
1990). In addition, activation of serotonergic neurons in
the ventromedial medulla produces a drop in blood pres-
sure and heart rate by inhibiting central sympathetic
outflow (Kalkman and Fozard, 1991). This effect is limited
to the medial serotonergic cell group in this region, with
stimulation of laterally located neurons inducing hyperten-
sion in these same animals. Numerous orphanin-contain-
ing neurons are located in the region of the noradrenergic
A5 cell group in the caudal mesencephalon and meten-
cephalon. This cell group is known to project to autonomic
nuclei of the brainstem and spinal cord (Byrum and
Guyenet, 1987), with direct spinal projections to the
intermediate gray and intermediolateral (sympathetic pre-
ganglionic) cell column in the spinal cord and to the
nucleus of the solitary tract. Chemical stimulation of
neurons in the A5 region has been reported to induce a fall
in blood pressure (Neil and Loewy, 1982). The localization
of orphanin within neurons in the dorsal raphe and
ventromedial medulla and within the region of the A5 cell
group raises the possibility of colocalization with noradren-
ergic or serotonergic projection neurons controlling blood
pressure, cardiac output, and sodium balance.
The nucleus of the solitary tract contains numerous
OFQ mRNA-expressing cells and immunoreactive neurons
and abundant ORL1 receptor (Anton et al., 1996). Auto-
nomic efferents from this nucleus project to the intermedio-
lateral cell column of the spinal cord, nucleus ambiguous,
dorsal motor nucleus of the vagal nerve, ventrolateral
medulla, A5 cell group, parabrachial nucleus, and numer-
ous forebrain regions (Saper, 1995). Solitary nucleus projec-
tions to the preganglionic parasympathetic neurons in the
medulla and sympathetic neurons in the spinal cord
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influence numerous autonomic responses. In addition,
efferents to the medullary reticular formation influence
gastrointestinal, cardiovascular, and respiratory reflexes.
The brainstem orphanin system is localized diffusely within
major autonomic control centers. Although initial studies
have demonstrated an OFQ influence on primarily cardio-
vascular function and water balance, this peptide may be
involved in several autonomic and physiologic functions,
including general arousal, cardiovascular tone, respira-
tory drive, gastrointestinal function, and general visceral
sensory feedback.
Special sensory systems. Brainstem special sensory
systems provide extensive input to higher centers through
strong olfactory, gustatory, and visceral sensory informa-
tion that regulates the medial preoptic area, anterior
hypothalamus, dorsomedial hypothalamus, and ventrome-
dial hypothalamus and through visual and auditory infor-
mation to the mammillary bodies. OFQ is present in
several nuclei within these circuits and probably plays
some role in the integration and/or processing of this
information.
OFQ is highly expressed within nuclei that integrate
visual information, particularly the nucleus of Darks-
chewitsch, pretectum, and superior colliculus, providing a
medium for OFQ involvement in visual sensory integra-
tion, as well modulation of output to the spinal cord, the
midline pontine and medullary nuclei, the hypothalamus,
and the intralaminar thalamic nuclei. In the forebrain, the
lateral mammillary nucleus contains a very dense plexus
of OFQ-containing neurons and fibers. This nucleus is
influenced strongly by both visual and auditory stimuli
and is thought to be involved the processing of visual and
auditory information, and it has been shown to have direct
cortical connections (Simerly, 1995). Although the majority
of brainstem auditory regions have little OFQ and ORL1
content, structures primarily involved with the integra-
tion of high frequency sound in the rat (Aitkin et al., 1984)
contain abundant OFQ expression. Such information is
integrated directly in the trapezoid body, lateral superior
olive, and inferior colliculus. Orphanin expression is strong
in the nucleus of the trapezoid body, which projects directly
to the lateral superior olive, which, in turn, projects to the
inferior colliculus. These structures contain moderate
amounts of ORL1 immunoreactivity (Anton et al., 1996) as
well as OFQ-containing cell bodies, supporting a role for
OFQ in the integration of high-frequency sounds. It is
important to note that, given the presence of OFQ and the
ORL1 receptor within the auditory nuclei described above,
as well as in the inferior olive and the vestibular system,
the OFQ system may be involved in the integration of
auditory and vestibular information and possibly plays a
major role in an animal’s ability to adapt to visual,
proprioceptive, and auditory cues in its environment.
Little is known concerning a role for OFQ in visual or
auditory processing, but a recent study in ORL1-deficient
mice has shown that these animals demonstrate an insuf-
ficient recovery of hearing ability after adaptation to sound
exposure (Nishi et al., 1997).
A brief mention should be made of the possible role of
orphanin in the integration of olfactory and gustatory
information. Cranial nerves that carry gustatory and
somatosensory axons from the oral cavity are distributed
throughout the nucleus of the solitary tract in a topographi-
cal fashion (Altschuler et al., 1989). Gustatory information
from the solitary nucleus is relayed to the parabrachial
nucleus. Gustatory neurons within the parabrachial
nucleus are located primarily in the medial part, where
OFQ is not present, but abundant ORL1 receptor immuno-
reactivity (Anton et al., 1996) is observed. The parabra-
chial nucleus relays gustatory information to the ventral
posteromedial thalamus, then to the dorsal insular cortex,
and also directly to the central nucleus of the amygdala.
Olfactory stimulus perception and integration also may be
modulated by OFQ. The entorhinal cortex, which contains
neurons with OFQ-like immunoreactivity and OFQ mRNA
expression, receives substantial olfactory input from the
olfactory bulbs and the piriform cortex. This structure, in
turn, projects by way of the perforant pathway to the hippocam-
pal formation and to other higher centers (Schwerdtfeger et
al., 1990). There are no data to date supporting a role for
orphanin in the processing of olfactory or gustatory informa-
tion. However, as discussed above, injections of OFQ into the
lateral ventricle of the rat appear to increase feeding
behavior (Pomonis et al., 1996). It is highly likely that
signals from gustatory and olfactory centers are important
in the complex series of behaviors involved with feeding.
Orphanin FQ, by its presence within major nuclei in these
systems, may be involved in the stimulatory effects of
intraventricular orphanin on feeding behavior.
CONCLUSIONS
We have demonstrated that OFQ, the novel endogenous
agonist of the ORL1 receptor, is distributed widely through-
out the CNS of the adult male rat. We have also established
a very close correlation between preproorphanin mRNA and
OFQ peptide expression. In addition, analysis of the immuno-
histochemical distribution of the ORL1 receptor demonstrates
correspondence of the orphanin peptide with its endogenous
receptor, providing the groundwork for study of specific
anatomic systems in deciphering the multiple behavioral
and physiologic roles of this neuropeptide. Orphanin FQ
and the ORL1 receptor are expressed in critical compo-
nents of numerous neural circuits, supporting their pos-
sible involvement in various CNS systems, including noci-
ception, modulation of the L-HPA stress axis, motivation
and reward, learning and memory, gross motor control,
balance and proprioception, sexual, aggressive, and inves-
tigatory behaviors, control of autonomic and physiologic
functions, and integration of special sensory input.
Although much claim has been made on naming this
molecule ‘‘nociceptin’’ due to its possible antagonism of
analgesic modalities, the distribution of the orphanin
system in the CNS is very diffuse and includes numerous
forebrain and brainstem circuits and systems. Orphanin
FQ and its receptor most likely play a major role in many
behaviors and physiologic functions, making nociceptin too
limiting a nomenclature for such an important neuropeptide.
We support the continued use of ‘‘orphanin FQ’’when referring
to this neuropeptide as we continue to unravel its role in the
CNS.
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